{"cells":[{"cell_type":"code","execution_count":14,"metadata":{"executionInfo":{"elapsed":1213,"status":"ok","timestamp":1728939976104,"user":{"displayName":"Cyro Queiroz","userId":"10205326658499773298"},"user_tz":180},"id":"WNnSViHy-Qnz"},"outputs":[],"source":["import pandas as pd\n","import requests\n","import json"]},{"cell_type":"code","execution_count":15,"metadata":{"executionInfo":{"elapsed":483,"status":"ok","timestamp":1728939976582,"user":{"displayName":"Cyro Queiroz","userId":"10205326658499773298"},"user_tz":180},"id":"JCKVXIx0-Td4"},"outputs":[],"source":["# Define the API endpoint\n","#type = [week, industry]\n","#sessionID = \n","#abstractAPI = \n","#dayID = (from 2 until gets nothin)\n","#presentationID = \n","\n","#daysurl = https://ueg2024.planner.documedias.systems/api/program/rooms/2?program_type={$type}&system=program_week_2024&program_mode=list&program_sort=date&filter_display_type=1,3&filter_group=is_not_child\n","sessionurl = \"https://ueg2024.planner.documedias.systems/api/program/sessions/80?program_type=week&system=program_week_2024\"\n","#abstracturl = https://ueg2024.planner.documedias.systems/api/program/presentations/2506?program_type=week&system=program_week_2024\n","\n","# Make the API request\n","responseSession = requests.get(sessionurl)\n","dataSession = responseSession.json()\n","\n","# ITERATE OVER EACH FIELD"]},{"cell_type":"code","execution_count":22,"metadata":{},"outputs":[{"name":"stdout","output_type":"stream","text":["Indication: ['Crohn', \"Crohn's disease\", 'IBD', 'inflammatory bowel disease', 'Ulcerative Colitis', 'Ulcerative', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']\n","Asset: ['Tulisokibart', 'Ustekinumab', 'Guselkumab', 'Upadacitinib', 'Risankizumab', 'Mirikizumab', 'Ozanimod', 'Etrasimod', 'CT-P13', 'ABX-464', 'MORF-057', 'VTX958', 'TEV-48574', 'Humira', 'PF-07054894', 'PF-07261271', 'Ritlecitinib', 'PF-06480605', 'Infliximab', 'Cimzia', 'Golimumab', 'Vedolizumab', 'SHR0302', 'Neihulizumab', 'TAK-279', 'Tysabri', 'AGMB-129']\n","Company Name: ['Merck', 'JnJ', 'Prometheus', 'AbbVie', 'Eli Lilly', 'BMS', 'Pfizer', 'Celltrion', 'Abivax', 'Morphic', 'Ventyx', 'Sanofi', 'UCB', 'Takeda', 'Reistone', 'Altru Bio', 'Biogen', 'Agomab', 'Boehringer', 'Incannex', 'Medibiofarma', 'EA Pharma', 'Gilead', 'Spyre', 'Mozart', 'Athos', 'Syneos']\n","MoA: ['TL1A', 'Anti-IL-12/23', 'Interleukin 23 antagonist', 'JAK inhibitor', 'S1PR modulators', 'Anti TNF', 'MiRNA-124 expression stimulants', 'alpha4ß7 integrin', 'TYK2 inhibitor', 'CCR6 antagonist', 'Janus kinase 3 inhibitor', 'Janus kinase 1 inhibitor', 'Apoptosis stimulants', 'Alpha4beta1 integrin', 'Transforming growth factor beta receptor 1', 'Kinase inhibitor', 'Cannabinoid agonist', 'ROR-gamma-t agonist', 'PPARg Partial Agonist', 'aIL23p19 + aTNF', 'Restore CD8 T cell function', 'Targeting gene A', 'CD30 ligand', 'Pegylated human adrenomedullin', 'Targets T cells subset', 'TREM-1 antibody', 'Ion channel protein Kv1.3 inh']\n","Other Keywords: ['Pediatric', 'Paediatric', 'Intestinal ultrasound', 'CDST', 'Artificial Intelligence', 'Machine Learning', 'ultrasound', 'Clinical Decision support tool', 'Clinical decision', 'IUS', 'Combination', 'Meta-analysis', 'Comparative', 'Sequencing', 'Comparison', 'Fatigue', 'Adolescent', '', '', '', '', '', '', '', '', '', '']\n"]}],"source":["import json\n","\n","# Assuming you've already loaded keywords_data from the JSON file\n","with open('keywords.json', 'r') as f:\n","    keywords_data = json.load(f)\n","\n","# Define the lists\n","indication = []\n","asset = []\n","company_name = []\n","MoA = []\n","other_keywords = []\n","\n","# Populate the lists from the keywords dictionary\n","for row in keywords_data['rows']:\n","    indication.append(row[0])\n","    asset.append(row[1])\n","    company_name.append(row[2])\n","    MoA.append(row[3])\n","    other_keywords.append(row[4])\n","\n","# Function to check if a keyword is present in the text\n","def find_matching_keyword(text, keywords):\n","    if not text:\n","        return None\n","    for keyword in keywords:\n","        if keyword and keyword.lower() in text.lower():\n","            return keyword\n","    return None\n","\n","# Print the lists to verify\n","print(\"Indication:\", indication)\n","print(\"Asset:\", asset)\n","print(\"Company Name:\", company_name)\n","print(\"MoA:\", MoA)\n","print(\"Other Keywords:\", other_keywords)\n"]},{"cell_type":"code","execution_count":23,"metadata":{},"outputs":[{"name":"stdout","output_type":"stream","text":["<i><u>B.E. Sands</u><sup>1</sup>, G. D’Haens<sup>2</sup>, S. Danese<sup>3</sup>, T. Hisamatsu<sup>4</sup>, W. Reinisch<sup>5</sup>, N.A. Terry<sup>6</sup>, L. Salese<sup>6</sup>, R. Van Rampelbergh<sup>7</sup>, Z. Yang<sup>6</sup>, J. Johanns<sup>6</sup>, G. DuVall<sup>8</sup>, N. Abu Farsakh<sup>9</sup>, R. Panaccione<sup>10</sup></i><br>\n","<div><sup>1</sup>Dr. Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States of America, <sup>2</sup>Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, Netherlands, <sup>3</sup>Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, <sup>4</sup>Department of Gastroenterology and Hepatology, Kyorin University, Tokyo, Japan, <sup>5</sup>Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria, <sup>6</sup>Janssen Research & Development, LLC, Spring House, United States of America, <sup>7</sup>Janssen Research & Development, Antwerp, Belgium, <sup>8</sup>Tyler Research Institute, LLC, Tyler, United States of America, <sup>9</sup>King Abdullah University Hospital, Irbid, Jordan, <sup>10</sup>Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Canada<br><br></div>\n","\n","            <div><strong>Introduction</strong>:&nbsp;GALAXI 2 &amp; 3 are identically designed 48-week, randomized, double-blind, double-dummy, placebo (PBO)- and active-comparator, treat-through registrational trials assessing the efficacy and safety of IV induction and SC maintenance therapy with guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, in participants (pts) with moderately to severely active Crohn’s disease (CD). Primary results of each study were previously reported; here we explore the impact of biologic therapy exposure on efficacy outcomes with GUS compared to PBO in the pooled GALAXI 2 &amp; 3 dataset.</div>\n","                <div><strong>Aims & Methods</strong>:&nbsp;Pts with inadequate response or intolerance to conventional therapy or biologic therapy (BIO-ir), active CD (CDAI 220–450 + mean daily SF&gt;3 or AP&gt;1), and SES-CD≥6 (≥4 for isolated ileal disease) were randomly assigned 2:2:2:1 at week (Wk) 0 to GUS 200mg IV q4w (x3)→100mg SC q8w, GUS 200mg IV q4w (x3)→200mg SC q4w, UST IV→SC, or PBO. In each trial, the composite co-primary endpoints were 1) clinical response at Wk12 + clinical remission at Wk48, and 2) clinical response at Wk12 + endoscopic response at Wk48, comparing each GUS regimen to PBO. Major secondary endpoints included clinical remission at Wk12 and endoscopic response at Wk12. Analyses of BIO-ir and BIO-naïve subgroups in the individual trials were prespecified; pooled analyses were performed post hoc.</div>\n","                <div><strong>Results</strong>:&nbsp;​In the pooled dataset, 52% (378/730) of pts randomized to PBO or GUS had a prior history of BIO-ir and 42% (305/730) were BIO-naïve (6% [47/730] had prior exposure to biologics but no documented failure). At Wk12, GUS achieved higher rates of clinical remission and endoscopic response compared to PBO in the overall population and BIO-ir and BIO-naïve subgroups (<strong>Table</strong>). For the composite co-primary endpoints, both GUS regimens also achieved higher rates of 1) clinical response at Wk12 + clinical remission at Wk48 and 2) clinical response at Wk12 + endoscopic response at Wk48 compared to PBO in the overall population and BIO-ir and BIO-naïve subgroups.<br><br><table style=\"width: 100%; margin-left: calc(0%);\" class=\"\"><tbody><tr><td style=\"width: 100%;\" colspan=\"10\" class=\"fr-selected-cell\"><strong>Ta</strong><strong>ble. Efficacy of guselkumab (GUS) and placebo (PBO) for short- and long-term clinical and endoscopic endpoints in all participants and BIO-ir and BIO-naïve subgroups in the pooled GALAXI 2 &amp; 3 dataset</strong><br></td></tr><tr><td style=\"width: 10.0069%;\" class=\"\"><br></td><td style=\"width: 30%; text-align: center;\" colspan=\"3\"><strong>Overall population</strong><br></td><td style=\"width: 29.9523%; text-align: center;\" colspan=\"3\"><strong>Participants with a history of inadequate response or intolerance to at least 1 prior biologic<sup>a</sup> (BIO-ir)</strong><br></td><td style=\"width: 30%; text-align: center;\" colspan=\"3\"><strong>Participants with no history of exposure to biologics<sup>a</sup> (BIO-naïve) </strong><br></td></tr><tr><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239);\" class=\"\"><br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=148<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=582<br></td><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=78<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=300<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=61<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=244<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical remission at Wk12</strong><br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\">28 (18.9%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">274 (47.1%)<br><strong>∆ 28.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">15 (19.2%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">138 (46.0%)<br><strong>∆ 26.9%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">10 (16.4%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">121 (49.6%)<br><strong>∆ 32.1%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Endoscopic response at Wk12</strong><br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">18 (12.2%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">215 (36.9%)<br><strong>∆ 25.2%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">5 (6.4%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">87 (29.0%)<br><strong>∆ 22.6%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">11 (18.0%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">113 (46.3%)<br><strong>∆ 27.7%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239);\" class=\"\"><br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=148<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=286<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=296<br></td><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=78<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=153<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=147<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=61<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=116<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=128<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical response at Wk12 + clinical remission at Wk48<br></strong>(composite co-primary endpoint)<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">18 (12.2%)<br></td><td style=\"width: 10%; text-align: center;\">137 (47.9%)<br><strong>∆ 35.8%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">152 (51.4%)<br><strong>∆ 39.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">10 (12.8%)<br></td><td style=\"width: 10%; text-align: center;\">70 (45.8%)<br><strong>∆ 33.2%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">73 (49.7%)<br><strong>∆ 37.4%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">7 (11.5%)<br></td><td style=\"width: 10%; text-align: center;\">60 (51.7%)<br><strong>∆ 40.4%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">70 (54.7%)<br><strong>∆ 41.8%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical response at Wk12 + endoscopic response at Wk48</strong><br>(composite co-primary endpoint)<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">8 (5.4%)<br></td><td style=\"width: 10%; text-align: center;\">104 (36.4%)<br><strong>∆ 30.7%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">110 (37.2%)<br><strong>∆ 31.8%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">4 (5.1%)<br></td><td style=\"width: 10%; text-align: center;\">55 (35.9%)<br><strong>∆ 30.9%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">46 (31.3%)<br><strong>∆ 26.7%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">4 (6.6%)<br></td><td style=\"width: 10%; text-align: center;\">47 (40.5%)<br><strong>∆ 33.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">56 (43.8%)<br><strong>∆ 36.5%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 100%;\" colspan=\"10\">Data are presented as n (%); ∆% (adjusted treatment difference) vs PBO; p-value vs PBO.<br>Adjusted treatment differences and p-values were based on the common risk difference by use of Mantel-Haenszel stratum weights and the Sato variance estimator. The stratification variables used are baseline CDAI score (≤300 or &gt;300), baseline SES-CD score (≤12 or &gt;12), BIO-ir status (Yes or No; this variable used only in analyses of the overall population), and baseline corticosteroid use (Yes or No). Population N values reflect the primary analysis set, defined as all randomized participants who received at least 1 (partial or complete) dose of study intervention and had a screening SES-CD score ≥6 (or ≥4 for participants with isolated ileal disease). PBO pts not in clinical response at week (Wk) 12 switched to UST.<br><br><u>Endpoint definitions</u>: clinical remission, CDAI &lt; 150; endoscopic response, ≥50% improvement from baseline in SES-CD or SES-CD ≤ 2; clinical response, ≥100-point reduction from baseline in CDAI or CDAI &lt; 150. Participants with treatment failure or missing data were considered to not have met the endpoint.<br><br>a. Anti-TNF agents or vedolizumab<br>b. Participants assigned to either GUS 200mg IV every 4 weeks (q4w) (x3)→100mg SC q8w or GUS 200mg IV q4w (x3)→200mg SC q4w. At the Wk 12 assessment, GUS participants had only received GUS IV.<br>c. Participants assigned to GUS 200mg IV q4w (x3)→100mg SC q8w<br>d.<sup> </sup>Participants assigned to GUS 200mg IV q4w (x3)→200mg SC q4w<br>* Nominal p-value<br></td></tr></tbody></table></div>\n","                <div><strong>Conclusion</strong>:&nbsp;In pooled analyses of the double-blind GALAXI 2 &amp; 3 trials, GUS was efficacious versus PBO in pts with CD regardless of prior biologic therapy exposure in both short-term (Wk12) endpoints and long-term (Wk12 + Wk48) composite endpoints.</div>\n","                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\n","                <div><strong>Disclosure</strong>:&nbsp;<strong >Bruce E. Sands</strong> reports potential conflicts of interest with AbbVie, Abivax, Adiso Therapeutics, Agomab, Alimentiv, Amgen, AnaptysBio, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celgene, Celltrion, ClostraBio, Equillium, Enthera, Evommune, Ferring, Fresenius Kabi, Galapagos, Genentech (Roche), Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Index Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Janssen, Kaleido, Kallyope, Lilly, Merck, Microbiotica, Mobius Care, Morphic Therapeutics, MRM Health, Pfizer, Nexus Therapeutics, Nimbus Discovery, Odyssey, Therapeutics, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Rasayana Therapeutics, Recludix Therapeutics, Reistone Biotherapeutics, Sun Pharma, Surrozen, Target RWE, Takeda, Teva, Theravance Biopharma, TLL Pharmaceutical, TR1X, Union Therapeutics and Ventyx Biosciences.<br><strong>Geert D’Haens</strong> reports potential conflicts of interest with AbbVie, Agomab, Alimentiv, AstraZeneca, AMT, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom, Galapagos, GlaxoSmithKline, Gossamerbio, Immunic, Index, Johnson &amp; Johnson, Kaleido, Origo, Pfizer, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity, and Protagonist Therapeutics Inc., Seres Health, and Takeda.<br><strong>Silvio Danese</strong> reports potential conflicts of interest with AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring, Gilead, Hospira, Inotrem, Janssen, Johnson &amp; Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity, Takeda, TiGenix, UCB, and Vifor.<br><strong>Tadakazu Hisamatsu</strong> reports potential conflicts of interest with AbbVie, Bristol Myers Squibb, Daiichi-Sankyo, EA Pharma Co, Ltd., Eli Lilly, Gilead Sciences, Janssen Research &amp; Development, LLC., JIMRO, Kissei Pharmaceutical Co, Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Inc., and Takeda Pharmaceutical Co., Ltd.<br><strong>Walter Reinisch</strong> reports potential conflicts of interest with AbbVie, Aesca, Agomab, Algernon, AltruBio, Amgen, AM, AMT, AOP Orphan, Aptalis, Arena, Astellas, AstraZeneca, Avaxia, Roland Berger, Bioclinica, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Calyx, Cellerix, Chemocentryx, Celgene, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest &amp; Young, Falk, Ferring, Fresenius, Galapagos, Gatehouse, Genentech, Gilead, Grünenthal, ICON, Immundiagnostik, Index, Inova, Intrinsic Imaging, Janssen, Johnson &amp; Johnson, Kyowa Hakko Kirin, Landos, Lipid, LivaNova, Mallinckrodt, Medahead, Medice, MedImmune, Millenium, Mitsubishi Tanabe, MSD, Nash, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pfizer, Pharmacosmos, PLS Education, Procter &amp; Gamble, Prometheus, Protagonist, Provention, Quell, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres, Setpointmedical, Sigmoid, Sublimity, Takeda, Teva, Therakos, Theravance, Tigenix, UCB, Vifor, Yakult, Zealand, Zyngenia, and 4SC.<br><strong>Natalie A. Terry</strong>, <strong>Leonardo Salese</strong>, <strong>Rian Van Rampelbergh</strong>, <strong>Zijiang Yang</strong>, and <strong>Jewel Johanns</strong> are employees of Janssen Research &amp; Development (a Johnson &amp; Johnson Company) and may own company stock/stock options.<br><strong>George DuVall</strong> reports potential conflicts of interest with Janssen.<br><strong>Niazy Abu Farsakh</strong><strong> </strong>reports potential conflicts of interest with Abbott, Amgen, Antanea medical services, Ferring, Hikma, Janssen, and Pfizer.<br><strong>Remo Panaccione </strong>reports potential conflicts of interest with Abbivax, Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus, Viatris, Ventyx, and UCB.</div>\n","        <div>\n","                    <br><strong>Keyword 1</strong>:&nbsp;Crohn's disease&nbsp;&nbsp;&nbsp;\n","                            <strong>Keyword 2</strong>:&nbsp;guselkumab&nbsp;&nbsp;&nbsp;\n","                    </div>\n","  \n","[]\n","<i><u>M. Barreiro-de Acosta</u><sup>1,2</sup>, L. Nieto-Garcia<sup>2</sup>, M. Poncela<sup>3</sup>, C.J. Gargallo-Puyuelo<sup>4</sup>, F. Rodriguez-Moranta<sup>5</sup>, D. Ceballos<sup>6</sup>, M.I. Calvo Moya<sup>7</sup>, S. Garcia-Lopez<sup>8</sup>, M. Aguas<sup>9</sup>, L. Zabalza<sup>10</sup>, C. Martinez Cuevas<sup>11</sup>, R. de Francisco<sup>12</sup>, I. Bastón-Rey<sup>1,13</sup>, F. Bermejo<sup>14</sup>, L. Madero<sup>15</sup>, M.D. Martín-Arranz<sup>16</sup>, M. Rivero<sup>17</sup>, I. Alonso-Abreu<sup>18</sup>, P. Varela Trastoy<sup>19</sup>, M.L. De Castro Parga<sup>20</sup>, B. Camps<sup>21</sup>, C. Martinez Pascual<sup>22</sup>, B. Sicilia<sup>23</sup>, J.P. Gisbert<sup>24</sup>, M. Piqueras<sup>25</sup>, C. Abril<sup>26</sup>, E. Brunet<sup>27</sup>, A. Hernandez Camba<sup>28</sup>, P. Fradejas<sup>29</sup>, Á. Ponferrada-Díaz<sup>30</sup>, M. Mañosa Ciria<sup>31</sup>, M. Algara San Nicolas<sup>32</sup>, J. Castro Poceiro<sup>33</sup>, J.A. Ferrer<sup>34</sup>, E. Ricart<sup>35</sup>, A. Elorza<sup>36</sup>, M.F. García Sepulcre<sup>37</sup>, P. Robledo<sup>38</sup>, M. Teller<sup>39</sup>, E. Sesé<sup>40</sup>, D. Busquets Casals<sup>41</sup>, F. Mesonero Gismero<sup>42</sup>, R. Pajares<sup>43</sup>, L. Bujanda Fernández de Piérola<sup>44</sup>, C. González-Muñoza<sup>45</sup>, D. Martin Rodriguez<sup>46</sup>, M.T. Diz-Lois Palomares<sup>47</sup>, I. Nicolas<sup>48</sup>, E. Domenech<sup>31</sup>, R. Ferreiro-Iglesias<sup>1,2</sup>, ENEIDA project of GETECCU</i><br>\n","<div><sup>1</sup>Complexo Hospitalario Universitario de Santiago, Gastroenterology, Santiago, Spain, <sup>2</sup>Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Santiago de Compostela, Spain, <sup>3</sup>Hospital General Universitario Gregorio Marañón.Instituto de Investigación Biomédica Gregorio Marañón (IiSGM), Madrid, Spain, <sup>4</sup>Hospital Clínico Universitario “Lozano Blesa”, IIS Aragón and CIBERehd, Zaragoza, Spain, <sup>5</sup>Hospital Universitario de Bellvitge, IDIBELL, Gastroenterology, Barcelona, Spain, <sup>6</sup>Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain, <sup>7</sup>Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology, Madrid, Spain, <sup>8</sup>Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain, <sup>9</sup>La Fe Universitary And Politecnic Hospital, Gastroenterology Unit, Valencia, Spain, <sup>10</sup>Hospital Universitario de Navarra, Gastroenterology, Pamplona, Spain, <sup>11</sup>Hospital Universitario Rio Hortega, Valladolid, Spain, <sup>12</sup>Hospital Universitario Central de Asturias and ISPA, Gastroenterology, Oviedo, Spain, <sup>13</sup>Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Santiago de CompostelaSsps, Spain, <sup>14</sup>H Fuenlabrada, Gastroenterology, Fuenlabrada, Spain, <sup>15</sup>Hospital General Universitario de Alicante and CIBERehd, Gastroenterology, Alicante, Spain, <sup>16</sup>Hospital La Paz, Gastroenterology, Madrid, Spain, <sup>17</sup>Marqués de Valdecilla Universitary Hospital, Gastroenterology, Santander, Spain, <sup>18</sup>Hospital Universitario de Canarias (H.U.C.), Santa Cruz de Tenerife, Spain, <sup>19</sup>Hospital de Cabueñes, Gijon, Spain, <sup>20</sup>Hospital Álvaro Cunqueiro, Estrutura Organizativa de Xestión Integrada de Vigo, Gastroenterology, Vigo, Spain, <sup>21</sup>Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Gastroenterology, Barcelona, Spain, <sup>22</sup>H.C.U.Virgen de la Arrixaca, Gastroenterology, Murcia, Spain, <sup>23</sup>Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain, <sup>24</sup>Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Gastroenterology, Madrid, Spain, <sup>25</sup>Consorci Sanitari Terrasa, Gastroenterology, Barcelona, Spain, <sup>26</sup>Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain, <sup>27</sup>Parc Tauli, Digestive, Sabadell, Spain, <sup>28</sup>Complejo Hospitalario Universitario Ntra. Sra. de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain, <sup>29</sup>Complejo Asistencial de Zamora, Gastroenterology, Zamora, Spain, <sup>30</sup>Hospital Infanta Leonor, Madrid, Spain, <sup>31</sup>Hospital Universitari Germans Trias I Pujol and CIBEREHD, Gastroenterology, Badalona, Spain, <sup>32</sup>H.12 Octubre, Madrid, Spain, <sup>33</sup>Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology, Barcelona, Spain, <sup>34</sup>Hospital Fundacion Alcorcon, Gastroenterology, Alcorcon, Spain, <sup>35</sup>Hospital Clínic i Provincial, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Gastroenterology, Barcelona, Spain, <sup>36</sup>Hospital de Galdakao-Usansolo, Gastroenterology, Galdakao, Spain, <sup>37</sup>Hospital General Universitario de Elche, Gastroenterology, Elche, Spain, <sup>38</sup>Hospital Universitario de Cáceres, Caceres, Spain, <sup>39</sup>Althaia Xarxa Assistencial universitaria de Manresa, Gastroenterology, Manresa, Spain, <sup>40</sup>Hospital Universitario Arnau de Vilanova, Gastroenterology, Lleida, Spain, <sup>41</sup>H. DE GIRONA DR. J. TRUETA/ICO GERONA, Gastroenterology, Girona, Spain, <sup>42</sup>Hospital Ramon y Cajal, Gastroenterology, Madrid, Spain, <sup>43</sup>Hospital Universitario Infanta Sofía, Gastroenterology, Madrid, Spain, <sup>44</sup>Hospital Universitario Donostia and  Biodonostia, San Sebastián, Spain, <sup>45</sup>Hospital Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, <sup>46</sup>Hospital Infanta Cristina, Madrid, Spain, <sup>47</sup>Hospital Universitario A Coruña, Gastroenterology, A Coruña, Spain, <sup>48</sup>Hospital General Universitario Reina Sofía, Gastroenterology, Murcia, Spain<br><br></div>\n","\n","            <div><strong>Introduction</strong>:&nbsp;Phase III trials have demonstrated the efficacy of risankizumab (RZB), this being the first humanised monoclonal IgG1 antibody which targets the interleukin 23 p19 subunit, in moderate-to-severe Crohn's disease (CD). However, real-world data in induction with this drug is scarce. The aim of the study was to assess the real-world short-term effectiveness and safety of RZB in multi-refractory patients with CD.</div>\n","                <div><strong>Aims & Methods</strong>:&nbsp;Adult CD patients that had received induction doses with RZB in the ENEIDA registry—a large prospectively maintained Spanish database promoted by the Spanish Working Group in Crohn’s and Colitis (GETECCU)— were included. Clinical and demographical data including number of previous biologics and advanced therapies were included. The primary endpoint was steroid-free clinical remission evaluated at any point between weeks 8 and 12 (Harvey-Bradshaw [HB] score &lt;5). Secondary endpoints included steroid free clinical remission at the end of follow-up, clinical, biochemical improvement (C-reactive protein (CRP) and/or faecal calprotectine (FC)), need for CD-related surgery and adverse events related with the drug. The data are presented as median (range), and frequencies and percentages. Statistical analysis was performed using the Chi-square or Fisher's test, and the Student-<em >t</em> test or U-Mann-Whitney test as appropriate.</div>\n","                <div><strong>Results</strong>:&nbsp;417 CD patients (52% male) were included: median age was 50 (18-84) years, median disease duration 14 years, 27% were smokers. Regarding Montreal classification, 49% were L1, 10% L2, and 38% L3. Most of the patients presented inflammatory pattern (47%), 32% presented structuring, 21% penetrating behavior and perianal disease was present in 24%. 48% had abdominal CD surgery and 41% presented extraintestinal manifestations. Only 8% received concomitant immunossupressives with RZB. Regarding previous exposure to biologics or JAK inhibitors, only 3% were naïve, 49% had been exposed to 1-2 advanced therapies and 48% to 3 or more biologics or JAKs. After induction 58% of the patients achieved steroid-free clinical remission and at the end of the follow-up steroid-free clinical remission was observed in 62% of the patients. Median FC decreased from week 530 μg/g (week 0) to 333 μg/g after induction (p &lt;0.001). Regarding CRP, this decreased from median 7 mg/L at week 0 to 4.7 mg/L after induction (p = 0.002). 15 patients (3.5%) underwent intestinal resection. 23 patients (5.5%) presented adverse events including 6 infections.</div>\n","                <div><strong>Conclusion</strong>:&nbsp;This is the largest cohort study of real-world data with RZB, and it includes highly refractory patients with CD and multiple prior drug failures. RZB induction provided a steroid-free clinical remission in nearly 60% of patients and a significative improvement in biomarkers. Safety was consistent with the known profile of RZB in previous trials.</div>\n","                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\n","                <div><strong>Disclosure</strong>:&nbsp;MBA has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, GALAPAGOS, Pfizer, Sandoz, Biogen, Fresenius, Lilly, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Adacyte and TillotsPharma.</div>\n","        <div>\n","                    <br><strong>Keyword 1</strong>:&nbsp;Risankizumab&nbsp;&nbsp;&nbsp;\n","                            <strong>Keyword 2</strong>:&nbsp;Crohn&nbsp;&nbsp;&nbsp;\n","                            <strong>Keyword 3</strong>:&nbsp;Induction\n","            </div>\n","  \n","[{'Session Date': '2024-10-14', 'Session Start Time': '08:30', 'Session End Time': '09:30', 'Session Timezone': 'CEST', 'Session Location': 'A3', 'Session Number': 80, 'Session Pathways': 'IBD', 'Session CME': 'Pfizer', 'Session Type': 'Abstract Session', 'Session Group': 3, 'Session Title': 'Ameliorating acute disease through novel treatment in IBD: Part 1', 'Session Description': None, 'Session Format': 'Live, Recording, Q&A', 'Presentation Date': '2024-10-14', 'Presentation Location': 'A3', 'Presentation Start Time': '08:30', 'Presentation End Time': '08:42', 'Presentation ID': 702, 'Presentation Number': 'OP042', 'Presentation Title': 'EFFICACY OF GUSELKUMAB VERSUS PLACEBO IN CROHN’S DISEASE BASED ON PRIOR RESPONSE/EXPOSURE TO BIOLOGIC THERAPY: RESULTS OF THE GALAXI 2 &AMP; 3 PHASE 3 STUDIES', 'Presentation Title (lowercase)': 'efficacy of guselkumab versus placebo in crohn’s disease based on prior response/exposure to biologic therapy: results of the galaxi 2 &amp; 3 phase 3 studies', 'Abstract Authors': 'Bruce E. Sands', 'Abstract Affiliations': 'Icahn School of Medicine at Mount Sinai', 'Abstract': '<i><u>B.E. Sands</u><sup>1</sup>, G. D’Haens<sup>2</sup>, S. Danese<sup>3</sup>, T. Hisamatsu<sup>4</sup>, W. Reinisch<sup>5</sup>, N.A. Terry<sup>6</sup>, L. Salese<sup>6</sup>, R. Van Rampelbergh<sup>7</sup>, Z. Yang<sup>6</sup>, J. Johanns<sup>6</sup>, G. DuVall<sup>8</sup>, N. Abu Farsakh<sup>9</sup>, R. Panaccione<sup>10</sup></i><br>\\r\\n<div><sup>1</sup>Dr. Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States of America, <sup>2</sup>Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, Netherlands, <sup>3</sup>Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, <sup>4</sup>Department of Gastroenterology and Hepatology, Kyorin University, Tokyo, Japan, <sup>5</sup>Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria, <sup>6</sup>Janssen Research & Development, LLC, Spring House, United States of America, <sup>7</sup>Janssen Research & Development, Antwerp, Belgium, <sup>8</sup>Tyler Research Institute, LLC, Tyler, United States of America, <sup>9</sup>King Abdullah University Hospital, Irbid, Jordan, <sup>10</sup>Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Canada<br><br></div>\\r\\n\\r\\n            <div><strong>Introduction</strong>:&nbsp;GALAXI 2 &amp; 3 are identically designed 48-week, randomized, double-blind, double-dummy, placebo (PBO)- and active-comparator, treat-through registrational trials assessing the efficacy and safety of IV induction and SC maintenance therapy with guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, in participants (pts) with moderately to severely active Crohn’s disease (CD). Primary results of each study were previously reported; here we explore the impact of biologic therapy exposure on efficacy outcomes with GUS compared to PBO in the pooled GALAXI 2 &amp; 3 dataset.</div>\\r\\n                <div><strong>Aims & Methods</strong>:&nbsp;Pts with inadequate response or intolerance to conventional therapy or biologic therapy (BIO-ir), active CD (CDAI 220–450 + mean daily SF&gt;3 or AP&gt;1), and SES-CD≥6 (≥4 for isolated ileal disease) were randomly assigned 2:2:2:1 at week (Wk) 0 to GUS 200mg IV q4w (x3)→100mg SC q8w, GUS 200mg IV q4w (x3)→200mg SC q4w, UST IV→SC, or PBO. In each trial, the composite co-primary endpoints were 1) clinical response at Wk12 + clinical remission at Wk48, and 2) clinical response at Wk12 + endoscopic response at Wk48, comparing each GUS regimen to PBO. Major secondary endpoints included clinical remission at Wk12 and endoscopic response at Wk12. Analyses of BIO-ir and BIO-naïve subgroups in the individual trials were prespecified; pooled analyses were performed post hoc.</div>\\r\\n                <div><strong>Results</strong>:&nbsp;\\u200bIn the pooled dataset, 52% (378/730) of pts randomized to PBO or GUS had a prior history of BIO-ir and 42% (305/730) were BIO-naïve (6% [47/730] had prior exposure to biologics but no documented failure). At Wk12, GUS achieved higher rates of clinical remission and endoscopic response compared to PBO in the overall population and BIO-ir and BIO-naïve subgroups (<strong>Table</strong>). For the composite co-primary endpoints, both GUS regimens also achieved higher rates of 1) clinical response at Wk12 + clinical remission at Wk48 and 2) clinical response at Wk12 + endoscopic response at Wk48 compared to PBO in the overall population and BIO-ir and BIO-naïve subgroups.<br><br><table style=\"width: 100%; margin-left: calc(0%);\" class=\"\"><tbody><tr><td style=\"width: 100%;\" colspan=\"10\" class=\"fr-selected-cell\"><strong>Ta</strong><strong>ble. Efficacy of guselkumab (GUS) and placebo (PBO) for short- and long-term clinical and endoscopic endpoints in all participants and BIO-ir and BIO-naïve subgroups in the pooled GALAXI 2 &amp; 3 dataset</strong><br></td></tr><tr><td style=\"width: 10.0069%;\" class=\"\"><br></td><td style=\"width: 30%; text-align: center;\" colspan=\"3\"><strong>Overall population</strong><br></td><td style=\"width: 29.9523%; text-align: center;\" colspan=\"3\"><strong>Participants with a history of inadequate response or intolerance to at least 1 prior biologic<sup>a</sup> (BIO-ir)</strong><br></td><td style=\"width: 30%; text-align: center;\" colspan=\"3\"><strong>Participants with no history of exposure to biologics<sup>a</sup> (BIO-naïve) </strong><br></td></tr><tr><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239);\" class=\"\"><br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=148<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=582<br></td><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=78<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=300<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=61<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=244<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical remission at Wk12</strong><br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\">28 (18.9%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">274 (47.1%)<br><strong>∆ 28.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">15 (19.2%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">138 (46.0%)<br><strong>∆ 26.9%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">10 (16.4%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">121 (49.6%)<br><strong>∆ 32.1%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Endoscopic response at Wk12</strong><br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">18 (12.2%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">215 (36.9%)<br><strong>∆ 25.2%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">5 (6.4%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">87 (29.0%)<br><strong>∆ 22.6%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">11 (18.0%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">113 (46.3%)<br><strong>∆ 27.7%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239);\" class=\"\"><br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=148<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=286<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=296<br></td><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=78<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=153<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=147<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=61<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=116<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=128<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical response at Wk12 + clinical remission at Wk48<br></strong>(composite co-primary endpoint)<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">18 (12.2%)<br></td><td style=\"width: 10%; text-align: center;\">137 (47.9%)<br><strong>∆ 35.8%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">152 (51.4%)<br><strong>∆ 39.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">10 (12.8%)<br></td><td style=\"width: 10%; text-align: center;\">70 (45.8%)<br><strong>∆ 33.2%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">73 (49.7%)<br><strong>∆ 37.4%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">7 (11.5%)<br></td><td style=\"width: 10%; text-align: center;\">60 (51.7%)<br><strong>∆ 40.4%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">70 (54.7%)<br><strong>∆ 41.8%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical response at Wk12 + endoscopic response at Wk48</strong><br>(composite co-primary endpoint)<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">8 (5.4%)<br></td><td style=\"width: 10%; text-align: center;\">104 (36.4%)<br><strong>∆ 30.7%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">110 (37.2%)<br><strong>∆ 31.8%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">4 (5.1%)<br></td><td style=\"width: 10%; text-align: center;\">55 (35.9%)<br><strong>∆ 30.9%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">46 (31.3%)<br><strong>∆ 26.7%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">4 (6.6%)<br></td><td style=\"width: 10%; text-align: center;\">47 (40.5%)<br><strong>∆ 33.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">56 (43.8%)<br><strong>∆ 36.5%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 100%;\" colspan=\"10\">Data are presented as n (%); ∆% (adjusted treatment difference) vs PBO; p-value vs PBO.<br>Adjusted treatment differences and p-values were based on the common risk difference by use of Mantel-Haenszel stratum weights and the Sato variance estimator. The stratification variables used are baseline CDAI score (≤300 or &gt;300), baseline SES-CD score (≤12 or &gt;12), BIO-ir status (Yes or No; this variable used only in analyses of the overall population), and baseline corticosteroid use (Yes or No). Population N values reflect the primary analysis set, defined as all randomized participants who received at least 1 (partial or complete) dose of study intervention and had a screening SES-CD score ≥6 (or ≥4 for participants with isolated ileal disease). PBO pts not in clinical response at week (Wk) 12 switched to UST.<br><br><u>Endpoint definitions</u>: clinical remission, CDAI &lt; 150; endoscopic response, ≥50% improvement from baseline in SES-CD or SES-CD ≤ 2; clinical response, ≥100-point reduction from baseline in CDAI or CDAI &lt; 150. Participants with treatment failure or missing data were considered to not have met the endpoint.<br><br>a. Anti-TNF agents or vedolizumab<br>b. Participants assigned to either GUS 200mg IV every 4 weeks (q4w) (x3)→100mg SC q8w or GUS 200mg IV q4w (x3)→200mg SC q4w. At the Wk 12 assessment, GUS participants had only received GUS IV.<br>c. Participants assigned to GUS 200mg IV q4w (x3)→100mg SC q8w<br>d.<sup> </sup>Participants assigned to GUS 200mg IV q4w (x3)→200mg SC q4w<br>* Nominal p-value<br></td></tr></tbody></table></div>\\r\\n                <div><strong>Conclusion</strong>:&nbsp;In pooled analyses of the double-blind GALAXI 2 &amp; 3 trials, GUS was efficacious versus PBO in pts with CD regardless of prior biologic therapy exposure in both short-term (Wk12) endpoints and long-term (Wk12 + Wk48) composite endpoints.</div>\\r\\n                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\\r\\n                <div><strong>Disclosure</strong>:&nbsp;<strong >Bruce E. Sands</strong> reports potential conflicts of interest with AbbVie, Abivax, Adiso Therapeutics, Agomab, Alimentiv, Amgen, AnaptysBio, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celgene, Celltrion, ClostraBio, Equillium, Enthera, Evommune, Ferring, Fresenius Kabi, Galapagos, Genentech (Roche), Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Index Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Janssen, Kaleido, Kallyope, Lilly, Merck, Microbiotica, Mobius Care, Morphic Therapeutics, MRM Health, Pfizer, Nexus Therapeutics, Nimbus Discovery, Odyssey, Therapeutics, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Rasayana Therapeutics, Recludix Therapeutics, Reistone Biotherapeutics, Sun Pharma, Surrozen, Target RWE, Takeda, Teva, Theravance Biopharma, TLL Pharmaceutical, TR1X, Union Therapeutics and Ventyx Biosciences.<br><strong>Geert D’Haens</strong> reports potential conflicts of interest with AbbVie, Agomab, Alimentiv, AstraZeneca, AMT, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom, Galapagos, GlaxoSmithKline, Gossamerbio, Immunic, Index, Johnson &amp; Johnson, Kaleido, Origo, Pfizer, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity, and Protagonist Therapeutics Inc., Seres Health, and Takeda.<br><strong>Silvio Danese</strong> reports potential conflicts of interest with AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring, Gilead, Hospira, Inotrem, Janssen, Johnson &amp; Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity, Takeda, TiGenix, UCB, and Vifor.<br><strong>Tadakazu Hisamatsu</strong> reports potential conflicts of interest with AbbVie, Bristol Myers Squibb, Daiichi-Sankyo, EA Pharma Co, Ltd., Eli Lilly, Gilead Sciences, Janssen Research &amp; Development, LLC., JIMRO, Kissei Pharmaceutical Co, Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Inc., and Takeda Pharmaceutical Co., Ltd.<br><strong>Walter Reinisch</strong> reports potential conflicts of interest with AbbVie, Aesca, Agomab, Algernon, AltruBio, Amgen, AM, AMT, AOP Orphan, Aptalis, Arena, Astellas, AstraZeneca, Avaxia, Roland Berger, Bioclinica, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Calyx, Cellerix, Chemocentryx, Celgene, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest &amp; Young, Falk, Ferring, Fresenius, Galapagos, Gatehouse, Genentech, Gilead, Grünenthal, ICON, Immundiagnostik, Index, Inova, Intrinsic Imaging, Janssen, Johnson &amp; Johnson, Kyowa Hakko Kirin, Landos, Lipid, LivaNova, Mallinckrodt, Medahead, Medice, MedImmune, Millenium, Mitsubishi Tanabe, MSD, Nash, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pfizer, Pharmacosmos, PLS Education, Procter &amp; Gamble, Prometheus, Protagonist, Provention, Quell, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres, Setpointmedical, Sigmoid, Sublimity, Takeda, Teva, Therakos, Theravance, Tigenix, UCB, Vifor, Yakult, Zealand, Zyngenia, and 4SC.<br><strong>Natalie A. Terry</strong>, <strong>Leonardo Salese</strong>, <strong>Rian Van Rampelbergh</strong>, <strong>Zijiang Yang</strong>, and <strong>Jewel Johanns</strong> are employees of Janssen Research &amp; Development (a Johnson &amp; Johnson Company) and may own company stock/stock options.<br><strong>George DuVall</strong> reports potential conflicts of interest with Janssen.<br><strong>Niazy Abu Farsakh</strong><strong> </strong>reports potential conflicts of interest with Abbott, Amgen, Antanea medical services, Ferring, Hikma, Janssen, and Pfizer.<br><strong>Remo Panaccione </strong>reports potential conflicts of interest with Abbivax, Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus, Viatris, Ventyx, and UCB.</div>\\r\\n        <div>\\r\\n                    <br><strong>Keyword 1</strong>:&nbsp;Crohn\\'s disease&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 2</strong>:&nbsp;guselkumab&nbsp;&nbsp;&nbsp;\\r\\n                    </div>\\r\\n  ', 'Abstract Url': 'https://programme.ueg.eu/week2024/#/details/presentations/1077', 'Company': None, 'Asset': 'Guselkumab', 'Indication': 'Crohn', 'MoA': None, 'Other Keywords': None}]\n","<i><u>D.T. Rubin</u><sup>1</sup>, A. Charabaty<sup>2</sup>, V. Jairath<sup>3</sup>, J. Walter<sup>4</sup>, K. McGinnis<sup>5</sup>, R. Moses<sup>5</sup>, S. Maier<sup>5</sup>, R. Escobar<sup>5</sup>, S.K. Baygani<sup>5</sup>, L. Zaremba-Pechmann<sup>5</sup>, T. Kobayashi<sup>6</sup></i><br>\n","<div><sup>1</sup>University of Chicago Medicine, Chicago, United States of America, <sup>2</sup>John Hopkins University, Baltimore, United States of America, <sup>3</sup>Alimentiv Inc., Gastroenterology, London, Canada, <sup>4</sup>Thomas Jefferson University Hospitals, Philadelphia, United States of America, <sup>5</sup>Eli Lilly and Company, Indianapolis, United States of America, <sup>6</sup>Kitasato University Kitasato Institute Hospital, Tokyo, Japan<br><br></div>\n","\n","            <div><strong>Introduction</strong>:&nbsp;The safety and efficacy of mirikizumab (miri), an anti-IL-23p19 antibody, for moderately-to-severely active ulcerative colitis (UC) have been shown in Phase 3 trials (LUCENT-1 and -2; NCT03518086, NCT03524092). Extended induction with 3 additional intravenous (IV) doses of miri induced clinical response at Week (W)24 in more than 50% of patients who did not initially achieve clinical response to induction with miri at W12. Among the clinical non-responders, some had achieved partial response at W12 (Table 1). We assessed response over time in clinical non-responders at the end of induction who received extended induction with miri for an additional 12W.</div>\n","                <div><strong>Aims & Methods</strong>:&nbsp;In LUCENT-1, patients (N=1281) were randomly assigned 3:1 to receive miri 300mg or placebo IV at W0, W4, and W8. Patients not achieving clinical response with miri 300mg IV at W12 of LUCENT-1 (n=272) received extended induction treatment with open-label miri 300mg IV at W12, W16, and W20 (LUCENT-2). Symptomatic remission, symptomatic response, bowel urgency (BU) remission, and BU change from baseline at W16 and W20 are reported (definitions in Table 1) in addition to the previously disclosed outcomes at W24. For categorical variables, number and percentage of patients who are responders/remitters were presented. For continuous variables, mean change from baseline with standard deviation (SD) was used. Missing data were imputed as non-response.</div>\n","                <div><strong>Results</strong>:&nbsp;Among patients who were clinical non-responders to 12W of initial induction treatment (n=272), 53 (19.5%); 73 (26.8%); 101 (37.1%) achieved symptomatic remission and 144 (52.9%); 169 (62.1%); 197 (72.4%) patients achieved symptomatic response at W16, W20, and W24, respectively. Among miri induction non-responders with Urgency Numeric Rating Scale (NRS) score ≥3 at induction baseline (n=256), 10.9% achieved BU remission at W16, 14.8% at W20, and 19.9% at W24. There was a 1.8±2.4 (mean±SD) point reduction in Urgency NRS scores at W16, 2.1±2.5 reduction at W20, and 2.5±2.7 reduction at W24 (Table 1).<br><br><table border=\"1\" cellspacing=\"0\" cellpadding=\"0\" align=\"left\" ><tbody><tr><td colspan=\"5\" valign=\"top\"><strong>Table 1. Clinical outcomes for the </strong><strong>mirikizumab induction non-responder patient population</strong></td></tr><tr><td><strong>Outcomes for miri IV extended induction</strong></td><td><strong>W12 (W0 extended induction)</strong><br><strong> </strong><br><strong>M</strong><strong>iri induction non-responders<sup>a</sup></strong><br><strong>300 miri IV, Q4W</strong><br><strong>N= 272</strong></td><td><strong>W16 (W4 extended induction)</strong><br><strong> </strong><br><strong>M</strong><strong>iri induction non-responders<sup>a</sup></strong><br><strong>300 miri IV, Q4W</strong><br><strong>N= 272</strong></td><td><strong>W20 (W8 extended induction)</strong><br><strong> </strong><br><strong>M</strong><strong>iri induction non-responders<sup>a</sup></strong><br><strong>300 miri IV, Q4W</strong><br><strong>N= 272</strong></td><td><strong>W24 (W12 extended induction)</strong><br><strong> </strong><br><strong>M</strong><strong>iri induction non-responders<sup>a</sup></strong><br><strong>300 miri IV, Q4W</strong><br><strong>N= 272</strong></td></tr><tr><td><strong>Clinical response<sup>b</sup> </strong></td><td>0</td><td>n/a</td><td>n/a</td><td>146 (53.7)</td></tr><tr><td valign=\"top\"><strong>Symptomatic remission<sup>c</sup> </strong></td><td>13 (4.8)</td><td>53 (19.5)</td><td>73 (26.8)</td><td>101 (37.1)</td></tr><tr><td valign=\"top\"><strong>Symptomatic response<sup>d</sup><sup> </sup></strong></td><td>83 (30.5)</td><td>144 (52.9)</td><td>169 (62.1)</td><td>197 (72.4)</td></tr><tr><td valign=\"top\"><strong>BU remission<sup>e</sup></strong><strong><sup> </sup></strong><strong>(Nx= 256) </strong></td><td>18 (7.0)</td><td>28 (10.9)</td><td>38 (14.8)</td><td>51 (19.9)</td></tr><tr><td valign=\"top\"><strong>BU change from baseline<sup>f</sup></strong><strong><sup> </sup></strong><strong>[mBOCF; mean (SD)]</strong></td><td>-1.2 (2.2)</td><td>-1.8 (2.4)</td><td>-2.1 (2.5)</td><td>-2.5 (2.7)</td></tr><tr><td colspan=\"5\" valign=\"top\">Data reported as n (%) unless otherwise indicated.<br><em>Abbreviations: BU=bowel urgency; IV=intravenous; mBOCF=modified baseline observation carried forward; miri=mirikizumab; N=patient population; n=patient subpopulation; Nx=number of</em><em> patients with Urgency Numeric Rating Scale ≥3 at induction baseline; Q4W= every four weeks; SD=standard deviation; W=week</em><br><sup>a</sup>The miri induction non-responder population only included patients who continued to the maintenance trial (LUCENT-2)<br><sup>b</sup>Defined as ≥2-point and ≥30% decrease in Modified Mayo Score from baseline; rectal bleeding =0 or 1 or ≥1-point decrease from baseline<br><sup>c</sup>Defined as stool frequency =0 or stool frequency =1 with ≥1-point decrease in Modified Mayo Score from baseline; rectal bleeding=0<br><sup>d</sup>Defined as at least a 30% decrease from baseline in the composite clinical endpoint of the sum of stool frequency and rectal bleeding subscores<br><sup>e</sup>Defined as Urgency Numeric Rating Scale score=0 or 1<br><sup>f</sup>Change from baseline in Urgency Numeric Rating Scale score; range 0 to 10; a lower score indicates less severe bowel urgency</td></tr></tbody></table></div>\n","                <div><strong>Conclusion</strong>:&nbsp;Among patients who were clinical non-responders to induction at W12, more than 50% achieved clinical response after 3 additional induction doses with miri. A proportion of patients benefited earlier from extended induction at W16 and W20, respectively, regarding symptomatic response and remission, and BU outcomes. The results demonstrate continued symptomatic improvement and further support the potential benefit of extended induction treatment.</div>\n","                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\n","                <div><strong>Disclosure</strong>:&nbsp;<strong>DR </strong>receives grants or contracts from Takeda, and discloses consultancy fees with Abbvie, Altrubio, Allergan, Inc., American College of Gastroenterology, Arena Pharmaceuticals, Athos Therapeutics, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Cornerstones Health, Inc. (non-profit), GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, GoDuRn, LLC, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Eli Lilly and Company, Materia Prima, Pfizer, Prometheus Biosciences, Reistone, Takeda and Techlab, Inc.<br><strong>AC</strong> is on the advisory board of and/or a consultant for and/or receives educational grants from Abbvie, Eli Lilly and Company, Janssen, Pfizer, and Takeda.<br><strong>VJ</strong> has received consulting/advisory board fees from AbbVie, Alimentiv Inc. (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Asieris, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Reistone Biopharma, Roche, Sandoz, Takeda and TopiVert, and speaker’s fees from AbbVie, Ferring, Galapagos, Janssen, Pfizer, Shire and Takeda.<br><strong>JW </strong>has received consultancy or advisory board fees from Medtronic and Eli Lilly and Company.<br><strong>KM, RM,<sup> </sup>SM, RE, SB</strong> are employees and minor shareholders of Eli Lilly and Company<sup> </sup><br><strong>LZ-P</strong> is an employee of HaaPACS GmbH and contractor for Eli Lilly and Company<br><strong>TK</strong> has received lecture fees from Abbie GK, Activaid, Alfresa Pharma, Janssen Pharmaceutical, JIMRO, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, Pfizer Japan, Takeda Pharmaceutical, Thermo Fisher Diagnostics and Zeria Pharmaceutical; research grants from Abbvie GK, Activaid, Alfresa Pharma, Bristol Myers Squibb, Eli Lilly Japan, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceutical, JMDC, Mochida Pharmaceutical, Nippon Kayaku, Pfizer Japan and Takeda Pharmaceutical; scholarship contributions from Mitsubishi Tanabe Pharma, Nippon Kayaku and Zeria Pharmaceutical; study group sponsorship by Abbvie GK, EA Pharma, JIMRO, Kyorin Pharmaceutical, Mochida Pharmaceutical, Otsuka Holdings and Zeria Pharmaceutical; and advisory or consultancy fees from Abbie GK, Activaid, Alfresa Pharma, EA Pharma, Janssen Pharmaceutical, KISSEI Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer Japan and Takeda Pharmaceutical.</div>\n","        <div>\n","                    <br><strong>Keyword 1</strong>:&nbsp;Ulcerative Colitis&nbsp;&nbsp;&nbsp;\n","                            <strong>Keyword 2</strong>:&nbsp;Mirikizumab&nbsp;&nbsp;&nbsp;\n","                            <strong>Keyword 3</strong>:&nbsp;Extended induction response\n","            </div>\n","  \n","[{'Session Date': '2024-10-14', 'Session Start Time': '08:30', 'Session End Time': '09:30', 'Session Timezone': 'CEST', 'Session Location': 'A3', 'Session Number': 80, 'Session Pathways': 'IBD', 'Session CME': 'Pfizer', 'Session Type': 'Abstract Session', 'Session Group': 3, 'Session Title': 'Ameliorating acute disease through novel treatment in IBD: Part 1', 'Session Description': None, 'Session Format': 'Live, Recording, Q&A', 'Presentation Date': '2024-10-14', 'Presentation Location': 'A3', 'Presentation Start Time': '08:30', 'Presentation End Time': '08:42', 'Presentation ID': 702, 'Presentation Number': 'OP042', 'Presentation Title': 'EFFICACY OF GUSELKUMAB VERSUS PLACEBO IN CROHN’S DISEASE BASED ON PRIOR RESPONSE/EXPOSURE TO BIOLOGIC THERAPY: RESULTS OF THE GALAXI 2 &AMP; 3 PHASE 3 STUDIES', 'Presentation Title (lowercase)': 'efficacy of guselkumab versus placebo in crohn’s disease based on prior response/exposure to biologic therapy: results of the galaxi 2 &amp; 3 phase 3 studies', 'Abstract Authors': 'Bruce E. Sands', 'Abstract Affiliations': 'Icahn School of Medicine at Mount Sinai', 'Abstract': '<i><u>B.E. Sands</u><sup>1</sup>, G. D’Haens<sup>2</sup>, S. Danese<sup>3</sup>, T. Hisamatsu<sup>4</sup>, W. Reinisch<sup>5</sup>, N.A. Terry<sup>6</sup>, L. Salese<sup>6</sup>, R. Van Rampelbergh<sup>7</sup>, Z. Yang<sup>6</sup>, J. Johanns<sup>6</sup>, G. DuVall<sup>8</sup>, N. Abu Farsakh<sup>9</sup>, R. Panaccione<sup>10</sup></i><br>\\r\\n<div><sup>1</sup>Dr. Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States of America, <sup>2</sup>Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, Netherlands, <sup>3</sup>Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, <sup>4</sup>Department of Gastroenterology and Hepatology, Kyorin University, Tokyo, Japan, <sup>5</sup>Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria, <sup>6</sup>Janssen Research & Development, LLC, Spring House, United States of America, <sup>7</sup>Janssen Research & Development, Antwerp, Belgium, <sup>8</sup>Tyler Research Institute, LLC, Tyler, United States of America, <sup>9</sup>King Abdullah University Hospital, Irbid, Jordan, <sup>10</sup>Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Canada<br><br></div>\\r\\n\\r\\n            <div><strong>Introduction</strong>:&nbsp;GALAXI 2 &amp; 3 are identically designed 48-week, randomized, double-blind, double-dummy, placebo (PBO)- and active-comparator, treat-through registrational trials assessing the efficacy and safety of IV induction and SC maintenance therapy with guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, in participants (pts) with moderately to severely active Crohn’s disease (CD). Primary results of each study were previously reported; here we explore the impact of biologic therapy exposure on efficacy outcomes with GUS compared to PBO in the pooled GALAXI 2 &amp; 3 dataset.</div>\\r\\n                <div><strong>Aims & Methods</strong>:&nbsp;Pts with inadequate response or intolerance to conventional therapy or biologic therapy (BIO-ir), active CD (CDAI 220–450 + mean daily SF&gt;3 or AP&gt;1), and SES-CD≥6 (≥4 for isolated ileal disease) were randomly assigned 2:2:2:1 at week (Wk) 0 to GUS 200mg IV q4w (x3)→100mg SC q8w, GUS 200mg IV q4w (x3)→200mg SC q4w, UST IV→SC, or PBO. In each trial, the composite co-primary endpoints were 1) clinical response at Wk12 + clinical remission at Wk48, and 2) clinical response at Wk12 + endoscopic response at Wk48, comparing each GUS regimen to PBO. Major secondary endpoints included clinical remission at Wk12 and endoscopic response at Wk12. Analyses of BIO-ir and BIO-naïve subgroups in the individual trials were prespecified; pooled analyses were performed post hoc.</div>\\r\\n                <div><strong>Results</strong>:&nbsp;\\u200bIn the pooled dataset, 52% (378/730) of pts randomized to PBO or GUS had a prior history of BIO-ir and 42% (305/730) were BIO-naïve (6% [47/730] had prior exposure to biologics but no documented failure). At Wk12, GUS achieved higher rates of clinical remission and endoscopic response compared to PBO in the overall population and BIO-ir and BIO-naïve subgroups (<strong>Table</strong>). For the composite co-primary endpoints, both GUS regimens also achieved higher rates of 1) clinical response at Wk12 + clinical remission at Wk48 and 2) clinical response at Wk12 + endoscopic response at Wk48 compared to PBO in the overall population and BIO-ir and BIO-naïve subgroups.<br><br><table style=\"width: 100%; margin-left: calc(0%);\" class=\"\"><tbody><tr><td style=\"width: 100%;\" colspan=\"10\" class=\"fr-selected-cell\"><strong>Ta</strong><strong>ble. Efficacy of guselkumab (GUS) and placebo (PBO) for short- and long-term clinical and endoscopic endpoints in all participants and BIO-ir and BIO-naïve subgroups in the pooled GALAXI 2 &amp; 3 dataset</strong><br></td></tr><tr><td style=\"width: 10.0069%;\" class=\"\"><br></td><td style=\"width: 30%; text-align: center;\" colspan=\"3\"><strong>Overall population</strong><br></td><td style=\"width: 29.9523%; text-align: center;\" colspan=\"3\"><strong>Participants with a history of inadequate response or intolerance to at least 1 prior biologic<sup>a</sup> (BIO-ir)</strong><br></td><td style=\"width: 30%; text-align: center;\" colspan=\"3\"><strong>Participants with no history of exposure to biologics<sup>a</sup> (BIO-naïve) </strong><br></td></tr><tr><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239);\" class=\"\"><br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=148<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=582<br></td><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=78<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=300<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=61<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=244<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical remission at Wk12</strong><br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\">28 (18.9%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">274 (47.1%)<br><strong>∆ 28.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">15 (19.2%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">138 (46.0%)<br><strong>∆ 26.9%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">10 (16.4%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">121 (49.6%)<br><strong>∆ 32.1%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Endoscopic response at Wk12</strong><br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">18 (12.2%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">215 (36.9%)<br><strong>∆ 25.2%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">5 (6.4%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">87 (29.0%)<br><strong>∆ 22.6%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">11 (18.0%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">113 (46.3%)<br><strong>∆ 27.7%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239);\" class=\"\"><br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=148<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=286<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=296<br></td><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=78<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=153<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=147<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=61<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=116<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=128<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical response at Wk12 + clinical remission at Wk48<br></strong>(composite co-primary endpoint)<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">18 (12.2%)<br></td><td style=\"width: 10%; text-align: center;\">137 (47.9%)<br><strong>∆ 35.8%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">152 (51.4%)<br><strong>∆ 39.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">10 (12.8%)<br></td><td style=\"width: 10%; text-align: center;\">70 (45.8%)<br><strong>∆ 33.2%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">73 (49.7%)<br><strong>∆ 37.4%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">7 (11.5%)<br></td><td style=\"width: 10%; text-align: center;\">60 (51.7%)<br><strong>∆ 40.4%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">70 (54.7%)<br><strong>∆ 41.8%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical response at Wk12 + endoscopic response at Wk48</strong><br>(composite co-primary endpoint)<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">8 (5.4%)<br></td><td style=\"width: 10%; text-align: center;\">104 (36.4%)<br><strong>∆ 30.7%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">110 (37.2%)<br><strong>∆ 31.8%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">4 (5.1%)<br></td><td style=\"width: 10%; text-align: center;\">55 (35.9%)<br><strong>∆ 30.9%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">46 (31.3%)<br><strong>∆ 26.7%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">4 (6.6%)<br></td><td style=\"width: 10%; text-align: center;\">47 (40.5%)<br><strong>∆ 33.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">56 (43.8%)<br><strong>∆ 36.5%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 100%;\" colspan=\"10\">Data are presented as n (%); ∆% (adjusted treatment difference) vs PBO; p-value vs PBO.<br>Adjusted treatment differences and p-values were based on the common risk difference by use of Mantel-Haenszel stratum weights and the Sato variance estimator. The stratification variables used are baseline CDAI score (≤300 or &gt;300), baseline SES-CD score (≤12 or &gt;12), BIO-ir status (Yes or No; this variable used only in analyses of the overall population), and baseline corticosteroid use (Yes or No). Population N values reflect the primary analysis set, defined as all randomized participants who received at least 1 (partial or complete) dose of study intervention and had a screening SES-CD score ≥6 (or ≥4 for participants with isolated ileal disease). PBO pts not in clinical response at week (Wk) 12 switched to UST.<br><br><u>Endpoint definitions</u>: clinical remission, CDAI &lt; 150; endoscopic response, ≥50% improvement from baseline in SES-CD or SES-CD ≤ 2; clinical response, ≥100-point reduction from baseline in CDAI or CDAI &lt; 150. Participants with treatment failure or missing data were considered to not have met the endpoint.<br><br>a. Anti-TNF agents or vedolizumab<br>b. Participants assigned to either GUS 200mg IV every 4 weeks (q4w) (x3)→100mg SC q8w or GUS 200mg IV q4w (x3)→200mg SC q4w. At the Wk 12 assessment, GUS participants had only received GUS IV.<br>c. Participants assigned to GUS 200mg IV q4w (x3)→100mg SC q8w<br>d.<sup> </sup>Participants assigned to GUS 200mg IV q4w (x3)→200mg SC q4w<br>* Nominal p-value<br></td></tr></tbody></table></div>\\r\\n                <div><strong>Conclusion</strong>:&nbsp;In pooled analyses of the double-blind GALAXI 2 &amp; 3 trials, GUS was efficacious versus PBO in pts with CD regardless of prior biologic therapy exposure in both short-term (Wk12) endpoints and long-term (Wk12 + Wk48) composite endpoints.</div>\\r\\n                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\\r\\n                <div><strong>Disclosure</strong>:&nbsp;<strong >Bruce E. Sands</strong> reports potential conflicts of interest with AbbVie, Abivax, Adiso Therapeutics, Agomab, Alimentiv, Amgen, AnaptysBio, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celgene, Celltrion, ClostraBio, Equillium, Enthera, Evommune, Ferring, Fresenius Kabi, Galapagos, Genentech (Roche), Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Index Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Janssen, Kaleido, Kallyope, Lilly, Merck, Microbiotica, Mobius Care, Morphic Therapeutics, MRM Health, Pfizer, Nexus Therapeutics, Nimbus Discovery, Odyssey, Therapeutics, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Rasayana Therapeutics, Recludix Therapeutics, Reistone Biotherapeutics, Sun Pharma, Surrozen, Target RWE, Takeda, Teva, Theravance Biopharma, TLL Pharmaceutical, TR1X, Union Therapeutics and Ventyx Biosciences.<br><strong>Geert D’Haens</strong> reports potential conflicts of interest with AbbVie, Agomab, Alimentiv, AstraZeneca, AMT, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom, Galapagos, GlaxoSmithKline, Gossamerbio, Immunic, Index, Johnson &amp; Johnson, Kaleido, Origo, Pfizer, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity, and Protagonist Therapeutics Inc., Seres Health, and Takeda.<br><strong>Silvio Danese</strong> reports potential conflicts of interest with AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring, Gilead, Hospira, Inotrem, Janssen, Johnson &amp; Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity, Takeda, TiGenix, UCB, and Vifor.<br><strong>Tadakazu Hisamatsu</strong> reports potential conflicts of interest with AbbVie, Bristol Myers Squibb, Daiichi-Sankyo, EA Pharma Co, Ltd., Eli Lilly, Gilead Sciences, Janssen Research &amp; Development, LLC., JIMRO, Kissei Pharmaceutical Co, Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Inc., and Takeda Pharmaceutical Co., Ltd.<br><strong>Walter Reinisch</strong> reports potential conflicts of interest with AbbVie, Aesca, Agomab, Algernon, AltruBio, Amgen, AM, AMT, AOP Orphan, Aptalis, Arena, Astellas, AstraZeneca, Avaxia, Roland Berger, Bioclinica, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Calyx, Cellerix, Chemocentryx, Celgene, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest &amp; Young, Falk, Ferring, Fresenius, Galapagos, Gatehouse, Genentech, Gilead, Grünenthal, ICON, Immundiagnostik, Index, Inova, Intrinsic Imaging, Janssen, Johnson &amp; Johnson, Kyowa Hakko Kirin, Landos, Lipid, LivaNova, Mallinckrodt, Medahead, Medice, MedImmune, Millenium, Mitsubishi Tanabe, MSD, Nash, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pfizer, Pharmacosmos, PLS Education, Procter &amp; Gamble, Prometheus, Protagonist, Provention, Quell, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres, Setpointmedical, Sigmoid, Sublimity, Takeda, Teva, Therakos, Theravance, Tigenix, UCB, Vifor, Yakult, Zealand, Zyngenia, and 4SC.<br><strong>Natalie A. Terry</strong>, <strong>Leonardo Salese</strong>, <strong>Rian Van Rampelbergh</strong>, <strong>Zijiang Yang</strong>, and <strong>Jewel Johanns</strong> are employees of Janssen Research &amp; Development (a Johnson &amp; Johnson Company) and may own company stock/stock options.<br><strong>George DuVall</strong> reports potential conflicts of interest with Janssen.<br><strong>Niazy Abu Farsakh</strong><strong> </strong>reports potential conflicts of interest with Abbott, Amgen, Antanea medical services, Ferring, Hikma, Janssen, and Pfizer.<br><strong>Remo Panaccione </strong>reports potential conflicts of interest with Abbivax, Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus, Viatris, Ventyx, and UCB.</div>\\r\\n        <div>\\r\\n                    <br><strong>Keyword 1</strong>:&nbsp;Crohn\\'s disease&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 2</strong>:&nbsp;guselkumab&nbsp;&nbsp;&nbsp;\\r\\n                    </div>\\r\\n  ', 'Abstract Url': 'https://programme.ueg.eu/week2024/#/details/presentations/1077', 'Company': None, 'Asset': 'Guselkumab', 'Indication': 'Crohn', 'MoA': None, 'Other Keywords': None}, {'Session Date': '2024-10-14', 'Session Start Time': '08:30', 'Session End Time': '09:30', 'Session Timezone': 'CEST', 'Session Location': 'A3', 'Session Number': 80, 'Session Pathways': 'IBD', 'Session CME': 'Pfizer', 'Session Type': 'Abstract Session', 'Session Group': 3, 'Session Title': 'Ameliorating acute disease through novel treatment in IBD: Part 1', 'Session Description': None, 'Session Format': 'Live, Recording, Q&A', 'Presentation Date': '2024-10-14', 'Presentation Location': 'A3', 'Presentation Start Time': '08:42', 'Presentation End Time': '08:54', 'Presentation ID': 703, 'Presentation Number': 'OP043', 'Presentation Title': 'REAL-WORLD SHORT-TERM EFFECTIVENESS OF RISANKIZUMAB IN REFRACTORY CROHN’S DISEASE: RISANCROHN STUDY FROM THE ENEIDA REGISTRY', 'Presentation Title (lowercase)': 'real-world short-term effectiveness of risankizumab in refractory crohn’s disease: risancrohn study from the eneida registry', 'Abstract Authors': 'Manuel Barreiro de Acosta', 'Abstract Affiliations': 'Health Research Institute of Santiago de Compostela (IDIS)', 'Abstract': \"<i><u>M. Barreiro-de Acosta</u><sup>1,2</sup>, L. Nieto-Garcia<sup>2</sup>, M. Poncela<sup>3</sup>, C.J. Gargallo-Puyuelo<sup>4</sup>, F. Rodriguez-Moranta<sup>5</sup>, D. Ceballos<sup>6</sup>, M.I. Calvo Moya<sup>7</sup>, S. Garcia-Lopez<sup>8</sup>, M. Aguas<sup>9</sup>, L. Zabalza<sup>10</sup>, C. Martinez Cuevas<sup>11</sup>, R. de Francisco<sup>12</sup>, I. Bastón-Rey<sup>1,13</sup>, F. Bermejo<sup>14</sup>, L. Madero<sup>15</sup>, M.D. Martín-Arranz<sup>16</sup>, M. Rivero<sup>17</sup>, I. Alonso-Abreu<sup>18</sup>, P. Varela Trastoy<sup>19</sup>, M.L. De Castro Parga<sup>20</sup>, B. Camps<sup>21</sup>, C. Martinez Pascual<sup>22</sup>, B. Sicilia<sup>23</sup>, J.P. Gisbert<sup>24</sup>, M. Piqueras<sup>25</sup>, C. Abril<sup>26</sup>, E. Brunet<sup>27</sup>, A. Hernandez Camba<sup>28</sup>, P. Fradejas<sup>29</sup>, Á. Ponferrada-Díaz<sup>30</sup>, M. Mañosa Ciria<sup>31</sup>, M. Algara San Nicolas<sup>32</sup>, J. Castro Poceiro<sup>33</sup>, J.A. Ferrer<sup>34</sup>, E. Ricart<sup>35</sup>, A. Elorza<sup>36</sup>, M.F. García Sepulcre<sup>37</sup>, P. Robledo<sup>38</sup>, M. Teller<sup>39</sup>, E. Sesé<sup>40</sup>, D. Busquets Casals<sup>41</sup>, F. Mesonero Gismero<sup>42</sup>, R. Pajares<sup>43</sup>, L. Bujanda Fernández de Piérola<sup>44</sup>, C. González-Muñoza<sup>45</sup>, D. Martin Rodriguez<sup>46</sup>, M.T. Diz-Lois Palomares<sup>47</sup>, I. Nicolas<sup>48</sup>, E. Domenech<sup>31</sup>, R. Ferreiro-Iglesias<sup>1,2</sup>, ENEIDA project of GETECCU</i><br>\\r\\n<div><sup>1</sup>Complexo Hospitalario Universitario de Santiago, Gastroenterology, Santiago, Spain, <sup>2</sup>Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Santiago de Compostela, Spain, <sup>3</sup>Hospital General Universitario Gregorio Marañón.Instituto de Investigación Biomédica Gregorio Marañón (IiSGM), Madrid, Spain, <sup>4</sup>Hospital Clínico Universitario “Lozano Blesa”, IIS Aragón and CIBERehd, Zaragoza, Spain, <sup>5</sup>Hospital Universitario de Bellvitge, IDIBELL, Gastroenterology, Barcelona, Spain, <sup>6</sup>Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain, <sup>7</sup>Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology, Madrid, Spain, <sup>8</sup>Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain, <sup>9</sup>La Fe Universitary And Politecnic Hospital, Gastroenterology Unit, Valencia, Spain, <sup>10</sup>Hospital Universitario de Navarra, Gastroenterology, Pamplona, Spain, <sup>11</sup>Hospital Universitario Rio Hortega, Valladolid, Spain, <sup>12</sup>Hospital Universitario Central de Asturias and ISPA, Gastroenterology, Oviedo, Spain, <sup>13</sup>Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Santiago de CompostelaSsps, Spain, <sup>14</sup>H Fuenlabrada, Gastroenterology, Fuenlabrada, Spain, <sup>15</sup>Hospital General Universitario de Alicante and CIBERehd, Gastroenterology, Alicante, Spain, <sup>16</sup>Hospital La Paz, Gastroenterology, Madrid, Spain, <sup>17</sup>Marqués de Valdecilla Universitary Hospital, Gastroenterology, Santander, Spain, <sup>18</sup>Hospital Universitario de Canarias (H.U.C.), Santa Cruz de Tenerife, Spain, <sup>19</sup>Hospital de Cabueñes, Gijon, Spain, <sup>20</sup>Hospital Álvaro Cunqueiro, Estrutura Organizativa de Xestión Integrada de Vigo, Gastroenterology, Vigo, Spain, <sup>21</sup>Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Gastroenterology, Barcelona, Spain, <sup>22</sup>H.C.U.Virgen de la Arrixaca, Gastroenterology, Murcia, Spain, <sup>23</sup>Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain, <sup>24</sup>Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Gastroenterology, Madrid, Spain, <sup>25</sup>Consorci Sanitari Terrasa, Gastroenterology, Barcelona, Spain, <sup>26</sup>Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain, <sup>27</sup>Parc Tauli, Digestive, Sabadell, Spain, <sup>28</sup>Complejo Hospitalario Universitario Ntra. Sra. de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain, <sup>29</sup>Complejo Asistencial de Zamora, Gastroenterology, Zamora, Spain, <sup>30</sup>Hospital Infanta Leonor, Madrid, Spain, <sup>31</sup>Hospital Universitari Germans Trias I Pujol and CIBEREHD, Gastroenterology, Badalona, Spain, <sup>32</sup>H.12 Octubre, Madrid, Spain, <sup>33</sup>Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology, Barcelona, Spain, <sup>34</sup>Hospital Fundacion Alcorcon, Gastroenterology, Alcorcon, Spain, <sup>35</sup>Hospital Clínic i Provincial, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Gastroenterology, Barcelona, Spain, <sup>36</sup>Hospital de Galdakao-Usansolo, Gastroenterology, Galdakao, Spain, <sup>37</sup>Hospital General Universitario de Elche, Gastroenterology, Elche, Spain, <sup>38</sup>Hospital Universitario de Cáceres, Caceres, Spain, <sup>39</sup>Althaia Xarxa Assistencial universitaria de Manresa, Gastroenterology, Manresa, Spain, <sup>40</sup>Hospital Universitario Arnau de Vilanova, Gastroenterology, Lleida, Spain, <sup>41</sup>H. DE GIRONA DR. J. TRUETA/ICO GERONA, Gastroenterology, Girona, Spain, <sup>42</sup>Hospital Ramon y Cajal, Gastroenterology, Madrid, Spain, <sup>43</sup>Hospital Universitario Infanta Sofía, Gastroenterology, Madrid, Spain, <sup>44</sup>Hospital Universitario Donostia and  Biodonostia, San Sebastián, Spain, <sup>45</sup>Hospital Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, <sup>46</sup>Hospital Infanta Cristina, Madrid, Spain, <sup>47</sup>Hospital Universitario A Coruña, Gastroenterology, A Coruña, Spain, <sup>48</sup>Hospital General Universitario Reina Sofía, Gastroenterology, Murcia, Spain<br><br></div>\\r\\n\\r\\n            <div><strong>Introduction</strong>:&nbsp;Phase III trials have demonstrated the efficacy of risankizumab (RZB), this being the first humanised monoclonal IgG1 antibody which targets the interleukin 23 p19 subunit, in moderate-to-severe Crohn's disease (CD). However, real-world data in induction with this drug is scarce. The aim of the study was to assess the real-world short-term effectiveness and safety of RZB in multi-refractory patients with CD.</div>\\r\\n                <div><strong>Aims & Methods</strong>:&nbsp;Adult CD patients that had received induction doses with RZB in the ENEIDA registry—a large prospectively maintained Spanish database promoted by the Spanish Working Group in Crohn’s and Colitis (GETECCU)— were included. Clinical and demographical data including number of previous biologics and advanced therapies were included. The primary endpoint was steroid-free clinical remission evaluated at any point between weeks 8 and 12 (Harvey-Bradshaw [HB] score &lt;5). Secondary endpoints included steroid free clinical remission at the end of follow-up, clinical, biochemical improvement (C-reactive protein (CRP) and/or faecal calprotectine (FC)), need for CD-related surgery and adverse events related with the drug. The data are presented as median (range), and frequencies and percentages. Statistical analysis was performed using the Chi-square or Fisher's test, and the Student-<em >t</em> test or U-Mann-Whitney test as appropriate.</div>\\r\\n                <div><strong>Results</strong>:&nbsp;417 CD patients (52% male) were included: median age was 50 (18-84) years, median disease duration 14 years, 27% were smokers. Regarding Montreal classification, 49% were L1, 10% L2, and 38% L3. Most of the patients presented inflammatory pattern (47%), 32% presented structuring, 21% penetrating behavior and perianal disease was present in 24%. 48% had abdominal CD surgery and 41% presented extraintestinal manifestations. Only 8% received concomitant immunossupressives with RZB. Regarding previous exposure to biologics or JAK inhibitors, only 3% were naïve, 49% had been exposed to 1-2 advanced therapies and 48% to 3 or more biologics or JAKs. After induction 58% of the patients achieved steroid-free clinical remission and at the end of the follow-up steroid-free clinical remission was observed in 62% of the patients. Median FC decreased from week 530 μg/g (week 0) to 333 μg/g after induction (p &lt;0.001). Regarding CRP, this decreased from median 7 mg/L at week 0 to 4.7 mg/L after induction (p = 0.002). 15 patients (3.5%) underwent intestinal resection. 23 patients (5.5%) presented adverse events including 6 infections.</div>\\r\\n                <div><strong>Conclusion</strong>:&nbsp;This is the largest cohort study of real-world data with RZB, and it includes highly refractory patients with CD and multiple prior drug failures. RZB induction provided a steroid-free clinical remission in nearly 60% of patients and a significative improvement in biomarkers. Safety was consistent with the known profile of RZB in previous trials.</div>\\r\\n                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\\r\\n                <div><strong>Disclosure</strong>:&nbsp;MBA has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, GALAPAGOS, Pfizer, Sandoz, Biogen, Fresenius, Lilly, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Adacyte and TillotsPharma.</div>\\r\\n        <div>\\r\\n                    <br><strong>Keyword 1</strong>:&nbsp;Risankizumab&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 2</strong>:&nbsp;Crohn&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 3</strong>:&nbsp;Induction\\r\\n            </div>\\r\\n  \", 'Abstract Url': 'https://programme.ueg.eu/week2024/#/details/presentations/2334', 'Company': None, 'Asset': 'Risankizumab', 'Indication': 'Crohn', 'MoA': None, 'Other Keywords': None}]\n","<i>D.T. Rubin<sup>1</sup>, A. Dignass<sup>2</sup>, J. Allegretti<sup>3</sup>, S. Yarandi<sup>4</sup>, K.-H. Huang<sup>4</sup>, M. Germinaro<sup>4</sup>, J. Zhan<sup>4</sup>, H. Zhang<sup>4</sup>, Y. Rayyan<sup>5</sup>, M. Saruta<sup>6</sup>, D. Balderramo<sup>7</sup>, B. Bressler<sup>8</sup>, L. Peyrin-Biroulet<sup>9</sup>, <u>T. Hisamatsu</u><sup>10</sup></i><br>\n","<div><sup>1</sup>University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States of America, <sup>2</sup>Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany, <sup>3</sup>Brigham and Women's Hospital Crohn's and Colitis Center, Boston, United States of America, <sup>4</sup>Janssen Research & Development, LLC, Spring House, United States of America, <sup>5</sup>The University of Jordan, School of Medicine, Amman, Jordan, <sup>6</sup>The Jikei University School of Medicine, Tokyo, Japan, <sup>7</sup>Hospital Privado Universitario de Córdoba, Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina, <sup>8</sup>University of British Columbia, Vancouver, Canada, <sup>9</sup>Nancy University Hospital, Université de Lorraine, Nancy, France, <sup>10</sup>Kyorin University School of Medicine, Tokyo, Japan<br><br></div>\n","\n","            <div><strong>Introduction</strong>:&nbsp;The QUASAR program (NCT04033445) evaluated guselkumab (GUS), a dual-acting interleukin (IL)-23p19 subunit inhibitor that potently neutralizes IL-23 and binds to CD64 (a receptor on cells that produce IL-23), in patients (pts) with moderately to severely active ulcerative colitis (UC). Induction Week 12 (Week I-12) nonresponders to intravenous (IV) GUS received subcutaneous (SC) GUS through Week I-24.<sup >1</sup> Week I‑24 responders were eligible for maintenance therapy. Here, we present the efficacy and safety of maintenance SC GUS among GUS Week I-24 responders.</div>\n","                <div><strong>Aims & Methods</strong>:&nbsp;Pts who were not in clinical response (see Table for definition) at Week I-12 after IV GUS 200 mg or 400 mg received SC GUS 200 mg at Weeks I-12, I-16, and I-20. Those who were in clinical response at Week I-24 (GUS Week I-24 responders) received SC GUS 200 mg every 4 weeks during the maintenance study in a blinded fashion and were evaluated as part of the nonrandomized study population. Clinical, symptomatic, endoscopic, histologic, and patient-reported outcome measures at maintenance Week 44 (Week M-44) and safety throughout the maintenance study are reported for GUS Week I-24 responders.</div>\n","                <div><strong>Results</strong>:&nbsp;Overall, 123 of 203 (60.6%) Week I-12 nonresponders to IV GUS achieved clinical response at Week I-24 and entered the maintenance study phase. Induction baseline characteristics of GUS Week I-24 responders were: 74.8% had severe disease (modified Mayo score 7-9), 77.2% had a Mayo endoscopy subscore of 3, median C-reactive protein was 5.0 mg/L (upper limit of normal, 3 mg/L), and 59.3% had a history of inadequate response or intolerance to biologic or Janus kinase inhibitor therapy for UC. At Week M‑44, 67.5% of the pts maintained clinical response and 30.1% were in clinical remission. Additional efficacy outcomes are shown in the Table. The proportion of GUS Week I-24 responders in symptomatic remission (defined as a stool frequency subscore of 0 or 1 and not increased from induction baseline, and a rectal bleeding subscore of 0) at maintenance baseline (58.5%) was sustained through Week M‑44 (56.9%). Adverse events (AEs) were reported for 78.0% of GUS Week I-24 responders, serious AEs for 5.7%, and serious infections for 1.6%. No opportunistic infections or deaths occurred. No new safety concerns were identified.<br><br><table style=\"width: 100%;\" class=\"\"><thead><tr><th colspan=\"2\" style=\"width: 99.8893%;\"><strong>Table. Efficacy Outcomes at Maintenance Week 44 for GUS Induction Week 12 Nonresponders Who Achieved Clinical Response<sup>a</sup> at Induction Week 24</strong></th></tr></thead><tbody><tr><td style=\"width: 71.3178%;\"><br></td><td style=\"width: 28.5715%; text-align: center;\"><strong>GUS 200 mg SC q4w</strong><br><strong>N=123</strong><br><strong>n (%)</strong><br></td></tr><tr><td style=\"width: 71.3178%;\">Clinical remission<sup>b</sup><br></td><td style=\"width: 28.5715%; text-align: center;\" class=\"\">37 (30.1)<br></td></tr><tr><td style=\"width: 71.3178%;\">Endoscopic improvement<sup>c </sup>/ Endoscopic normalization (remission)<sup>d</sup><br></td><td style=\"width: 28.5715%; text-align: center;\">44 (35.8) / 21 (17.1)<br></td></tr><tr><td style=\"width: 71.3178%;\">Corticosteroid-free clinical remission<sup>e</sup><br></td><td style=\"width: 28.5715%; text-align: center;\">37 (30.1)<br></td></tr><tr><td style=\"width: 71.3178%;\">Maintenance of clinical response<sup>f</sup><br></td><td style=\"width: 28.5715%; text-align: center;\">83 (67.5)<br></td></tr><tr><td style=\"width: 71.3178%;\">Histologic-endoscopic muscosal improvement<sup>g</sup><br></td><td style=\"width: 28.5715%; text-align: center;\">34 (27.6)<br></td></tr><tr><td style=\"width: 71.3178%;\">Fatigue response<sup>h</sup><br></td><td style=\"width: 28.5715%; text-align: center;\">49 (39.8)<br></td></tr><tr><td style=\"width: 71.3178%;\" class=\"\">Maintenance of clinical remission<sup>i</sup>, N=20<br></td><td style=\"width: 28.5715%; text-align: center;\">10 (50.0)<br></td></tr><tr><td style=\"width: 99.8893%;\" colspan=\"2\" class=\"fr-selected-cell\">GUS=guselkumab; PROMIS=Patient-Reported Outcomes Measurement Information System; pts=patients; q4w=every 4 weeks; SC=subcutaneous; Week M-44=maintenance Week 44.<br>Note: Includes only pts with modified Mayo score 5-9 at induction baseline.<br><sup>a</sup> Clinical response was defined as a decrease from induction baseline in the modified Mayo score by ≥30% and ≥2 points, with either a ≥1-point decrease from induction baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1.<br><sup>b </sup>Clinical remission was defined as a Mayo stool frequency subscore of 0 or 1 and not increased from induction baseline, a Mayo rectal bleeding subscore of 0, and a Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.<br><sup>c </sup>Endoscopic improvement was defined as an endoscopy subscore of 0 or 1 with no friability present on the endoscopy.<br><sup>d </sup>Endoscopic normalization (remission) was defined as an endoscopy subscore of 0.<br><sup>e </sup>Corticosteroid-free clinical remission was defined as clinical remission at Week M-44 without any use of corticosteroids for ≥8 weeks prior to Week M-44.<br><sup>f </sup>Maintenance of clinical response was defined as clinical response at Week M-44 among pts in clinical response at maintenance baseline.<br><sup>g</sup> Histologic-endoscopic muscosal improvement was defined as achieving a combination of histologic improvement (defined as neutrophil infiltration in &lt;5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system [i.e., Geboes score ≤3.1]) and endoscopic improvement.<br><sup>h</sup> Fatigue response was defined as a ≥7-point improvement from induction baseline in the PROMIS Fatigue Short Form 7a.<br><sup>i </sup>Maintenance of clinical remission was defined as clinical remission at Week M-44 among pts in clinical remission at maintenance baseline.<br></td></tr></tbody></table></div>\n","                <div><strong>Conclusion</strong>:&nbsp;In this refractory population of GUS Week I-24 responders, maintenance treatment with GUS provided clinical benefit across a range of clinically relevant efficacy endpoints. Safety results were consistent with the overall population and safety profile of GUS in its approved indications.</div>\n","                                        <div><strong>References</strong>:&nbsp;1. Bressler B, et al. <em >Am J Gastroenterol</em>. 2023;118(10S):806-807.</div>\n","                <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\n","                <div><strong>Disclosure</strong>:&nbsp;<strong>D. T. Rubin: </strong>research funding from Takeda; consultant to AbbVie, Altrubio, Allergan, Arena, Aslan, Athos, Bellatrix, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corp/Syneos, Connect, GalenPharma/Atlantica, Genentech/Roche, InDex, Ironwood, Iterative Scopes, Janssen, Lilly, Pfizer, Prometheus, Reistone, Takeda, and Techlab; and co-founder of Cornerstones Health.<br><strong>A. Dignass:</strong> fees for participation in clinical trials, review activities (data monitoring boards, statistical analysis, endpoint committees) from Abivax, AbbVie, Bristol Myers Squibb, Dr Falk Foundation, Galapagos, Gilead, Janssen, and Pfizer; consultancy fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Dr Falk Foundation, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Roche, Sandoz, Stada, Takeda, Tillotts, and Vifor Pharma; payment for lectures/speaker’s bureaus from AbbVie, Biogen, CED Service GmbH, Celltrion, Falk Foundation, Ferring, Galapagos, Gilead, High5MD, Janssen, Materia Prima, MedToday, MSD, Pfizer, Sandoz, Takeda, Tillotts, and Vifor Pharma; payment for manuscript preparation from Abbvie, Falk Foundation, Janssen, Takeda, Thieme, and UniMed Verlag.<br><strong>J. R. Allegretti: </strong>consultant for AbbVie, Adiso, Ferring, Finch, Iterative Scopes, Janssen, Merck, Pfizer, Roivant, and Seres Therapeutics; speaker for AbbVie, Bristol Myer Squibb, and Janssen; and research support from Janssen, Merck, and Pfizer.<br><strong>Y. Rayyan</strong>: fees for participating in clinical trials for Janssen as principal investigator and payment from lectures including service on speaker’s bureaus from Janssen, AbbVie, and Amgen.<br><strong>M. Saruta: </strong>grants or contracts from Mochida, Zeria Pharma, EA Pharma, Kissei, and EPS Corporation; and payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from AbbVie GK, Janssen, Mitsubishi Tanabe Pharma, Takeda, EA Pharma, Gilead Sciences, and Kissei.<br><strong>D. Balderramo: </strong>advisor/speaker fees from AbbVie, Janssen, Pfizer, Takeda, and Amgen; and travel/congress support from AbbVie, Janssen, Takeda, and Ferring.<br><strong>B. Bressler: </strong>advisor/speaker for AbbVie, Bristol Myers Squibb, Ferring, Janssen, Merck, Novartis, Organon, Pfizer, Sandoz, and Takeda; advisor for Alimentiv, Allergan, Amgen, AMT, Bausch Health, Bristol Myers Squibb, Celgene, Celltrion, Eupraxia Fresenius Kabi, Genentech/Roche, Gilead, Iterative Scopes, Jamp, Merck, Microbiome Insights, Mylan, Pendopharm, Protagonist, and Viatris; research support from AbbVie, Amgen, Business Intelligence, Bristol Myers Squibb, Genentech/Roche, GlaxoSmithKline, Janssen, Merck, and Qu Biologic; and holds stock options in Qu Biologic.<br><strong>L. Peyrin-Biroulet: </strong>consultant for AbbVie, Abivax, Alimentiv, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, Bristol Myers Squibb, Celltrion, Connect, Cytoki, Lilly, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech/Roche, Gilead, Gossamer Bio, GlaxoSmithKline, HAC-Pharma, IAG, InDex, Inotrem, Janssen, Medac, Mopac, Morphic, MSD, Norgine, Novartis, OM, ONO, OSE, Pandion, Par’Immune, Pfizer, Prometheus, Protagonist, Roche, Sandoz, Takeda, Theravance, Thermo Fisher, Tigenix, Tillots, Viatris, Vifor, and Ysopia; grants from Celltrion, Fresenius Kabi, and Takeda; honorarium for lectures from AbbVie, Amgen, Arena, Biogen, Celltrion, Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, Janssen, Medac, MSD, Pfizer, Sandoz, Takeda, Tillots, Viatris, and Vifor; and fees from AbbVie, Adacyte, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Celltrion, CONNECT Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, HAC-Pharma, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Norgine, Nordic Pharma, Novartis, OM Pharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Par’Immune, Pfizer, Prometheus, Protagonist, Roche, Sanofi, Sandoz, Takeda, Theravance, Thermo Fisher, Tigenix, Tillots, Viatris, Vifor, Ysopia, Abivax, Samsung, Ventyx, Roivant, and Vectivbio.<br><strong>T. Hisamatsu: </strong>grant support from AbbVie, Daiichi-Sankyo, EA Pharma, JIMRO, Mitsubishi Tanabe Pharma, Mochida, Nippon Kayaku, Pfizer, and Takeda; consulting fees from EA Pharma, Janssen Research &amp; Development, Gilead Sciences, Lilly, and Bristol Myers Squibb; and lecture fees from AbbVie, EA Pharma, Mitsubishi Tanabe Pharma, Takeda, Mochida, and Kissei.<br><strong>S. Yarandi, K.-H. G. Huang, M. Germinaro, J. Zhan, </strong>and<strong> H. Zhang: </strong>employees of Johnson &amp; Johnson and own company stock/stock options.</div>\n","        <div>\n","                    <br><strong>Keyword 1</strong>:&nbsp;ulcerative colitis&nbsp;&nbsp;&nbsp;\n","                            <strong>Keyword 2</strong>:&nbsp;guselkumab&nbsp;&nbsp;&nbsp;\n","                            <strong>Keyword 3</strong>:&nbsp;clinical response\n","            </div>\n","  \n","[{'Session Date': '2024-10-14', 'Session Start Time': '08:30', 'Session End Time': '09:30', 'Session Timezone': 'CEST', 'Session Location': 'A3', 'Session Number': 80, 'Session Pathways': 'IBD', 'Session CME': 'Pfizer', 'Session Type': 'Abstract Session', 'Session Group': 3, 'Session Title': 'Ameliorating acute disease through novel treatment in IBD: Part 1', 'Session Description': None, 'Session Format': 'Live, Recording, Q&A', 'Presentation Date': '2024-10-14', 'Presentation Location': 'A3', 'Presentation Start Time': '08:30', 'Presentation End Time': '08:42', 'Presentation ID': 702, 'Presentation Number': 'OP042', 'Presentation Title': 'EFFICACY OF GUSELKUMAB VERSUS PLACEBO IN CROHN’S DISEASE BASED ON PRIOR RESPONSE/EXPOSURE TO BIOLOGIC THERAPY: RESULTS OF THE GALAXI 2 &AMP; 3 PHASE 3 STUDIES', 'Presentation Title (lowercase)': 'efficacy of guselkumab versus placebo in crohn’s disease based on prior response/exposure to biologic therapy: results of the galaxi 2 &amp; 3 phase 3 studies', 'Abstract Authors': 'Bruce E. Sands', 'Abstract Affiliations': 'Icahn School of Medicine at Mount Sinai', 'Abstract': '<i><u>B.E. Sands</u><sup>1</sup>, G. D’Haens<sup>2</sup>, S. Danese<sup>3</sup>, T. Hisamatsu<sup>4</sup>, W. Reinisch<sup>5</sup>, N.A. Terry<sup>6</sup>, L. Salese<sup>6</sup>, R. Van Rampelbergh<sup>7</sup>, Z. Yang<sup>6</sup>, J. Johanns<sup>6</sup>, G. DuVall<sup>8</sup>, N. Abu Farsakh<sup>9</sup>, R. Panaccione<sup>10</sup></i><br>\\r\\n<div><sup>1</sup>Dr. Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States of America, <sup>2</sup>Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, Netherlands, <sup>3</sup>Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, <sup>4</sup>Department of Gastroenterology and Hepatology, Kyorin University, Tokyo, Japan, <sup>5</sup>Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria, <sup>6</sup>Janssen Research & Development, LLC, Spring House, United States of America, <sup>7</sup>Janssen Research & Development, Antwerp, Belgium, <sup>8</sup>Tyler Research Institute, LLC, Tyler, United States of America, <sup>9</sup>King Abdullah University Hospital, Irbid, Jordan, <sup>10</sup>Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Canada<br><br></div>\\r\\n\\r\\n            <div><strong>Introduction</strong>:&nbsp;GALAXI 2 &amp; 3 are identically designed 48-week, randomized, double-blind, double-dummy, placebo (PBO)- and active-comparator, treat-through registrational trials assessing the efficacy and safety of IV induction and SC maintenance therapy with guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, in participants (pts) with moderately to severely active Crohn’s disease (CD). Primary results of each study were previously reported; here we explore the impact of biologic therapy exposure on efficacy outcomes with GUS compared to PBO in the pooled GALAXI 2 &amp; 3 dataset.</div>\\r\\n                <div><strong>Aims & Methods</strong>:&nbsp;Pts with inadequate response or intolerance to conventional therapy or biologic therapy (BIO-ir), active CD (CDAI 220–450 + mean daily SF&gt;3 or AP&gt;1), and SES-CD≥6 (≥4 for isolated ileal disease) were randomly assigned 2:2:2:1 at week (Wk) 0 to GUS 200mg IV q4w (x3)→100mg SC q8w, GUS 200mg IV q4w (x3)→200mg SC q4w, UST IV→SC, or PBO. In each trial, the composite co-primary endpoints were 1) clinical response at Wk12 + clinical remission at Wk48, and 2) clinical response at Wk12 + endoscopic response at Wk48, comparing each GUS regimen to PBO. Major secondary endpoints included clinical remission at Wk12 and endoscopic response at Wk12. Analyses of BIO-ir and BIO-naïve subgroups in the individual trials were prespecified; pooled analyses were performed post hoc.</div>\\r\\n                <div><strong>Results</strong>:&nbsp;\\u200bIn the pooled dataset, 52% (378/730) of pts randomized to PBO or GUS had a prior history of BIO-ir and 42% (305/730) were BIO-naïve (6% [47/730] had prior exposure to biologics but no documented failure). At Wk12, GUS achieved higher rates of clinical remission and endoscopic response compared to PBO in the overall population and BIO-ir and BIO-naïve subgroups (<strong>Table</strong>). For the composite co-primary endpoints, both GUS regimens also achieved higher rates of 1) clinical response at Wk12 + clinical remission at Wk48 and 2) clinical response at Wk12 + endoscopic response at Wk48 compared to PBO in the overall population and BIO-ir and BIO-naïve subgroups.<br><br><table style=\"width: 100%; margin-left: calc(0%);\" class=\"\"><tbody><tr><td style=\"width: 100%;\" colspan=\"10\" class=\"fr-selected-cell\"><strong>Ta</strong><strong>ble. Efficacy of guselkumab (GUS) and placebo (PBO) for short- and long-term clinical and endoscopic endpoints in all participants and BIO-ir and BIO-naïve subgroups in the pooled GALAXI 2 &amp; 3 dataset</strong><br></td></tr><tr><td style=\"width: 10.0069%;\" class=\"\"><br></td><td style=\"width: 30%; text-align: center;\" colspan=\"3\"><strong>Overall population</strong><br></td><td style=\"width: 29.9523%; text-align: center;\" colspan=\"3\"><strong>Participants with a history of inadequate response or intolerance to at least 1 prior biologic<sup>a</sup> (BIO-ir)</strong><br></td><td style=\"width: 30%; text-align: center;\" colspan=\"3\"><strong>Participants with no history of exposure to biologics<sup>a</sup> (BIO-naïve) </strong><br></td></tr><tr><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239);\" class=\"\"><br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=148<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=582<br></td><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=78<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=300<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=61<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=244<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical remission at Wk12</strong><br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\">28 (18.9%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">274 (47.1%)<br><strong>∆ 28.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">15 (19.2%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">138 (46.0%)<br><strong>∆ 26.9%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">10 (16.4%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">121 (49.6%)<br><strong>∆ 32.1%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Endoscopic response at Wk12</strong><br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">18 (12.2%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">215 (36.9%)<br><strong>∆ 25.2%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">5 (6.4%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">87 (29.0%)<br><strong>∆ 22.6%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">11 (18.0%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">113 (46.3%)<br><strong>∆ 27.7%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239);\" class=\"\"><br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=148<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=286<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=296<br></td><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=78<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=153<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=147<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=61<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=116<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=128<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical response at Wk12 + clinical remission at Wk48<br></strong>(composite co-primary endpoint)<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">18 (12.2%)<br></td><td style=\"width: 10%; text-align: center;\">137 (47.9%)<br><strong>∆ 35.8%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">152 (51.4%)<br><strong>∆ 39.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">10 (12.8%)<br></td><td style=\"width: 10%; text-align: center;\">70 (45.8%)<br><strong>∆ 33.2%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">73 (49.7%)<br><strong>∆ 37.4%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">7 (11.5%)<br></td><td style=\"width: 10%; text-align: center;\">60 (51.7%)<br><strong>∆ 40.4%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">70 (54.7%)<br><strong>∆ 41.8%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical response at Wk12 + endoscopic response at Wk48</strong><br>(composite co-primary endpoint)<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">8 (5.4%)<br></td><td style=\"width: 10%; text-align: center;\">104 (36.4%)<br><strong>∆ 30.7%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">110 (37.2%)<br><strong>∆ 31.8%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">4 (5.1%)<br></td><td style=\"width: 10%; text-align: center;\">55 (35.9%)<br><strong>∆ 30.9%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">46 (31.3%)<br><strong>∆ 26.7%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">4 (6.6%)<br></td><td style=\"width: 10%; text-align: center;\">47 (40.5%)<br><strong>∆ 33.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">56 (43.8%)<br><strong>∆ 36.5%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 100%;\" colspan=\"10\">Data are presented as n (%); ∆% (adjusted treatment difference) vs PBO; p-value vs PBO.<br>Adjusted treatment differences and p-values were based on the common risk difference by use of Mantel-Haenszel stratum weights and the Sato variance estimator. The stratification variables used are baseline CDAI score (≤300 or &gt;300), baseline SES-CD score (≤12 or &gt;12), BIO-ir status (Yes or No; this variable used only in analyses of the overall population), and baseline corticosteroid use (Yes or No). Population N values reflect the primary analysis set, defined as all randomized participants who received at least 1 (partial or complete) dose of study intervention and had a screening SES-CD score ≥6 (or ≥4 for participants with isolated ileal disease). PBO pts not in clinical response at week (Wk) 12 switched to UST.<br><br><u>Endpoint definitions</u>: clinical remission, CDAI &lt; 150; endoscopic response, ≥50% improvement from baseline in SES-CD or SES-CD ≤ 2; clinical response, ≥100-point reduction from baseline in CDAI or CDAI &lt; 150. Participants with treatment failure or missing data were considered to not have met the endpoint.<br><br>a. Anti-TNF agents or vedolizumab<br>b. Participants assigned to either GUS 200mg IV every 4 weeks (q4w) (x3)→100mg SC q8w or GUS 200mg IV q4w (x3)→200mg SC q4w. At the Wk 12 assessment, GUS participants had only received GUS IV.<br>c. Participants assigned to GUS 200mg IV q4w (x3)→100mg SC q8w<br>d.<sup> </sup>Participants assigned to GUS 200mg IV q4w (x3)→200mg SC q4w<br>* Nominal p-value<br></td></tr></tbody></table></div>\\r\\n                <div><strong>Conclusion</strong>:&nbsp;In pooled analyses of the double-blind GALAXI 2 &amp; 3 trials, GUS was efficacious versus PBO in pts with CD regardless of prior biologic therapy exposure in both short-term (Wk12) endpoints and long-term (Wk12 + Wk48) composite endpoints.</div>\\r\\n                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\\r\\n                <div><strong>Disclosure</strong>:&nbsp;<strong >Bruce E. Sands</strong> reports potential conflicts of interest with AbbVie, Abivax, Adiso Therapeutics, Agomab, Alimentiv, Amgen, AnaptysBio, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celgene, Celltrion, ClostraBio, Equillium, Enthera, Evommune, Ferring, Fresenius Kabi, Galapagos, Genentech (Roche), Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Index Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Janssen, Kaleido, Kallyope, Lilly, Merck, Microbiotica, Mobius Care, Morphic Therapeutics, MRM Health, Pfizer, Nexus Therapeutics, Nimbus Discovery, Odyssey, Therapeutics, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Rasayana Therapeutics, Recludix Therapeutics, Reistone Biotherapeutics, Sun Pharma, Surrozen, Target RWE, Takeda, Teva, Theravance Biopharma, TLL Pharmaceutical, TR1X, Union Therapeutics and Ventyx Biosciences.<br><strong>Geert D’Haens</strong> reports potential conflicts of interest with AbbVie, Agomab, Alimentiv, AstraZeneca, AMT, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom, Galapagos, GlaxoSmithKline, Gossamerbio, Immunic, Index, Johnson &amp; Johnson, Kaleido, Origo, Pfizer, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity, and Protagonist Therapeutics Inc., Seres Health, and Takeda.<br><strong>Silvio Danese</strong> reports potential conflicts of interest with AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring, Gilead, Hospira, Inotrem, Janssen, Johnson &amp; Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity, Takeda, TiGenix, UCB, and Vifor.<br><strong>Tadakazu Hisamatsu</strong> reports potential conflicts of interest with AbbVie, Bristol Myers Squibb, Daiichi-Sankyo, EA Pharma Co, Ltd., Eli Lilly, Gilead Sciences, Janssen Research &amp; Development, LLC., JIMRO, Kissei Pharmaceutical Co, Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Inc., and Takeda Pharmaceutical Co., Ltd.<br><strong>Walter Reinisch</strong> reports potential conflicts of interest with AbbVie, Aesca, Agomab, Algernon, AltruBio, Amgen, AM, AMT, AOP Orphan, Aptalis, Arena, Astellas, AstraZeneca, Avaxia, Roland Berger, Bioclinica, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Calyx, Cellerix, Chemocentryx, Celgene, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest &amp; Young, Falk, Ferring, Fresenius, Galapagos, Gatehouse, Genentech, Gilead, Grünenthal, ICON, Immundiagnostik, Index, Inova, Intrinsic Imaging, Janssen, Johnson &amp; Johnson, Kyowa Hakko Kirin, Landos, Lipid, LivaNova, Mallinckrodt, Medahead, Medice, MedImmune, Millenium, Mitsubishi Tanabe, MSD, Nash, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pfizer, Pharmacosmos, PLS Education, Procter &amp; Gamble, Prometheus, Protagonist, Provention, Quell, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres, Setpointmedical, Sigmoid, Sublimity, Takeda, Teva, Therakos, Theravance, Tigenix, UCB, Vifor, Yakult, Zealand, Zyngenia, and 4SC.<br><strong>Natalie A. Terry</strong>, <strong>Leonardo Salese</strong>, <strong>Rian Van Rampelbergh</strong>, <strong>Zijiang Yang</strong>, and <strong>Jewel Johanns</strong> are employees of Janssen Research &amp; Development (a Johnson &amp; Johnson Company) and may own company stock/stock options.<br><strong>George DuVall</strong> reports potential conflicts of interest with Janssen.<br><strong>Niazy Abu Farsakh</strong><strong> </strong>reports potential conflicts of interest with Abbott, Amgen, Antanea medical services, Ferring, Hikma, Janssen, and Pfizer.<br><strong>Remo Panaccione </strong>reports potential conflicts of interest with Abbivax, Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus, Viatris, Ventyx, and UCB.</div>\\r\\n        <div>\\r\\n                    <br><strong>Keyword 1</strong>:&nbsp;Crohn\\'s disease&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 2</strong>:&nbsp;guselkumab&nbsp;&nbsp;&nbsp;\\r\\n                    </div>\\r\\n  ', 'Abstract Url': 'https://programme.ueg.eu/week2024/#/details/presentations/1077', 'Company': None, 'Asset': 'Guselkumab', 'Indication': 'Crohn', 'MoA': None, 'Other Keywords': None}, {'Session Date': '2024-10-14', 'Session Start Time': '08:30', 'Session End Time': '09:30', 'Session Timezone': 'CEST', 'Session Location': 'A3', 'Session Number': 80, 'Session Pathways': 'IBD', 'Session CME': 'Pfizer', 'Session Type': 'Abstract Session', 'Session Group': 3, 'Session Title': 'Ameliorating acute disease through novel treatment in IBD: Part 1', 'Session Description': None, 'Session Format': 'Live, Recording, Q&A', 'Presentation Date': '2024-10-14', 'Presentation Location': 'A3', 'Presentation Start Time': '08:42', 'Presentation End Time': '08:54', 'Presentation ID': 703, 'Presentation Number': 'OP043', 'Presentation Title': 'REAL-WORLD SHORT-TERM EFFECTIVENESS OF RISANKIZUMAB IN REFRACTORY CROHN’S DISEASE: RISANCROHN STUDY FROM THE ENEIDA REGISTRY', 'Presentation Title (lowercase)': 'real-world short-term effectiveness of risankizumab in refractory crohn’s disease: risancrohn study from the eneida registry', 'Abstract Authors': 'Manuel Barreiro de Acosta', 'Abstract Affiliations': 'Health Research Institute of Santiago de Compostela (IDIS)', 'Abstract': \"<i><u>M. Barreiro-de Acosta</u><sup>1,2</sup>, L. Nieto-Garcia<sup>2</sup>, M. Poncela<sup>3</sup>, C.J. Gargallo-Puyuelo<sup>4</sup>, F. Rodriguez-Moranta<sup>5</sup>, D. Ceballos<sup>6</sup>, M.I. Calvo Moya<sup>7</sup>, S. Garcia-Lopez<sup>8</sup>, M. Aguas<sup>9</sup>, L. Zabalza<sup>10</sup>, C. Martinez Cuevas<sup>11</sup>, R. de Francisco<sup>12</sup>, I. Bastón-Rey<sup>1,13</sup>, F. Bermejo<sup>14</sup>, L. Madero<sup>15</sup>, M.D. Martín-Arranz<sup>16</sup>, M. Rivero<sup>17</sup>, I. Alonso-Abreu<sup>18</sup>, P. Varela Trastoy<sup>19</sup>, M.L. De Castro Parga<sup>20</sup>, B. Camps<sup>21</sup>, C. Martinez Pascual<sup>22</sup>, B. Sicilia<sup>23</sup>, J.P. Gisbert<sup>24</sup>, M. Piqueras<sup>25</sup>, C. Abril<sup>26</sup>, E. Brunet<sup>27</sup>, A. Hernandez Camba<sup>28</sup>, P. Fradejas<sup>29</sup>, Á. Ponferrada-Díaz<sup>30</sup>, M. Mañosa Ciria<sup>31</sup>, M. Algara San Nicolas<sup>32</sup>, J. Castro Poceiro<sup>33</sup>, J.A. Ferrer<sup>34</sup>, E. Ricart<sup>35</sup>, A. Elorza<sup>36</sup>, M.F. García Sepulcre<sup>37</sup>, P. Robledo<sup>38</sup>, M. Teller<sup>39</sup>, E. Sesé<sup>40</sup>, D. Busquets Casals<sup>41</sup>, F. Mesonero Gismero<sup>42</sup>, R. Pajares<sup>43</sup>, L. Bujanda Fernández de Piérola<sup>44</sup>, C. González-Muñoza<sup>45</sup>, D. Martin Rodriguez<sup>46</sup>, M.T. Diz-Lois Palomares<sup>47</sup>, I. Nicolas<sup>48</sup>, E. Domenech<sup>31</sup>, R. Ferreiro-Iglesias<sup>1,2</sup>, ENEIDA project of GETECCU</i><br>\\r\\n<div><sup>1</sup>Complexo Hospitalario Universitario de Santiago, Gastroenterology, Santiago, Spain, <sup>2</sup>Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Santiago de Compostela, Spain, <sup>3</sup>Hospital General Universitario Gregorio Marañón.Instituto de Investigación Biomédica Gregorio Marañón (IiSGM), Madrid, Spain, <sup>4</sup>Hospital Clínico Universitario “Lozano Blesa”, IIS Aragón and CIBERehd, Zaragoza, Spain, <sup>5</sup>Hospital Universitario de Bellvitge, IDIBELL, Gastroenterology, Barcelona, Spain, <sup>6</sup>Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain, <sup>7</sup>Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology, Madrid, Spain, <sup>8</sup>Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain, <sup>9</sup>La Fe Universitary And Politecnic Hospital, Gastroenterology Unit, Valencia, Spain, <sup>10</sup>Hospital Universitario de Navarra, Gastroenterology, Pamplona, Spain, <sup>11</sup>Hospital Universitario Rio Hortega, Valladolid, Spain, <sup>12</sup>Hospital Universitario Central de Asturias and ISPA, Gastroenterology, Oviedo, Spain, <sup>13</sup>Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Santiago de CompostelaSsps, Spain, <sup>14</sup>H Fuenlabrada, Gastroenterology, Fuenlabrada, Spain, <sup>15</sup>Hospital General Universitario de Alicante and CIBERehd, Gastroenterology, Alicante, Spain, <sup>16</sup>Hospital La Paz, Gastroenterology, Madrid, Spain, <sup>17</sup>Marqués de Valdecilla Universitary Hospital, Gastroenterology, Santander, Spain, <sup>18</sup>Hospital Universitario de Canarias (H.U.C.), Santa Cruz de Tenerife, Spain, <sup>19</sup>Hospital de Cabueñes, Gijon, Spain, <sup>20</sup>Hospital Álvaro Cunqueiro, Estrutura Organizativa de Xestión Integrada de Vigo, Gastroenterology, Vigo, Spain, <sup>21</sup>Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Gastroenterology, Barcelona, Spain, <sup>22</sup>H.C.U.Virgen de la Arrixaca, Gastroenterology, Murcia, Spain, <sup>23</sup>Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain, <sup>24</sup>Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Gastroenterology, Madrid, Spain, <sup>25</sup>Consorci Sanitari Terrasa, Gastroenterology, Barcelona, Spain, <sup>26</sup>Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain, <sup>27</sup>Parc Tauli, Digestive, Sabadell, Spain, <sup>28</sup>Complejo Hospitalario Universitario Ntra. Sra. de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain, <sup>29</sup>Complejo Asistencial de Zamora, Gastroenterology, Zamora, Spain, <sup>30</sup>Hospital Infanta Leonor, Madrid, Spain, <sup>31</sup>Hospital Universitari Germans Trias I Pujol and CIBEREHD, Gastroenterology, Badalona, Spain, <sup>32</sup>H.12 Octubre, Madrid, Spain, <sup>33</sup>Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology, Barcelona, Spain, <sup>34</sup>Hospital Fundacion Alcorcon, Gastroenterology, Alcorcon, Spain, <sup>35</sup>Hospital Clínic i Provincial, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Gastroenterology, Barcelona, Spain, <sup>36</sup>Hospital de Galdakao-Usansolo, Gastroenterology, Galdakao, Spain, <sup>37</sup>Hospital General Universitario de Elche, Gastroenterology, Elche, Spain, <sup>38</sup>Hospital Universitario de Cáceres, Caceres, Spain, <sup>39</sup>Althaia Xarxa Assistencial universitaria de Manresa, Gastroenterology, Manresa, Spain, <sup>40</sup>Hospital Universitario Arnau de Vilanova, Gastroenterology, Lleida, Spain, <sup>41</sup>H. DE GIRONA DR. J. TRUETA/ICO GERONA, Gastroenterology, Girona, Spain, <sup>42</sup>Hospital Ramon y Cajal, Gastroenterology, Madrid, Spain, <sup>43</sup>Hospital Universitario Infanta Sofía, Gastroenterology, Madrid, Spain, <sup>44</sup>Hospital Universitario Donostia and  Biodonostia, San Sebastián, Spain, <sup>45</sup>Hospital Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, <sup>46</sup>Hospital Infanta Cristina, Madrid, Spain, <sup>47</sup>Hospital Universitario A Coruña, Gastroenterology, A Coruña, Spain, <sup>48</sup>Hospital General Universitario Reina Sofía, Gastroenterology, Murcia, Spain<br><br></div>\\r\\n\\r\\n            <div><strong>Introduction</strong>:&nbsp;Phase III trials have demonstrated the efficacy of risankizumab (RZB), this being the first humanised monoclonal IgG1 antibody which targets the interleukin 23 p19 subunit, in moderate-to-severe Crohn's disease (CD). However, real-world data in induction with this drug is scarce. The aim of the study was to assess the real-world short-term effectiveness and safety of RZB in multi-refractory patients with CD.</div>\\r\\n                <div><strong>Aims & Methods</strong>:&nbsp;Adult CD patients that had received induction doses with RZB in the ENEIDA registry—a large prospectively maintained Spanish database promoted by the Spanish Working Group in Crohn’s and Colitis (GETECCU)— were included. Clinical and demographical data including number of previous biologics and advanced therapies were included. The primary endpoint was steroid-free clinical remission evaluated at any point between weeks 8 and 12 (Harvey-Bradshaw [HB] score &lt;5). Secondary endpoints included steroid free clinical remission at the end of follow-up, clinical, biochemical improvement (C-reactive protein (CRP) and/or faecal calprotectine (FC)), need for CD-related surgery and adverse events related with the drug. The data are presented as median (range), and frequencies and percentages. Statistical analysis was performed using the Chi-square or Fisher's test, and the Student-<em >t</em> test or U-Mann-Whitney test as appropriate.</div>\\r\\n                <div><strong>Results</strong>:&nbsp;417 CD patients (52% male) were included: median age was 50 (18-84) years, median disease duration 14 years, 27% were smokers. Regarding Montreal classification, 49% were L1, 10% L2, and 38% L3. Most of the patients presented inflammatory pattern (47%), 32% presented structuring, 21% penetrating behavior and perianal disease was present in 24%. 48% had abdominal CD surgery and 41% presented extraintestinal manifestations. Only 8% received concomitant immunossupressives with RZB. Regarding previous exposure to biologics or JAK inhibitors, only 3% were naïve, 49% had been exposed to 1-2 advanced therapies and 48% to 3 or more biologics or JAKs. After induction 58% of the patients achieved steroid-free clinical remission and at the end of the follow-up steroid-free clinical remission was observed in 62% of the patients. Median FC decreased from week 530 μg/g (week 0) to 333 μg/g after induction (p &lt;0.001). Regarding CRP, this decreased from median 7 mg/L at week 0 to 4.7 mg/L after induction (p = 0.002). 15 patients (3.5%) underwent intestinal resection. 23 patients (5.5%) presented adverse events including 6 infections.</div>\\r\\n                <div><strong>Conclusion</strong>:&nbsp;This is the largest cohort study of real-world data with RZB, and it includes highly refractory patients with CD and multiple prior drug failures. RZB induction provided a steroid-free clinical remission in nearly 60% of patients and a significative improvement in biomarkers. Safety was consistent with the known profile of RZB in previous trials.</div>\\r\\n                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\\r\\n                <div><strong>Disclosure</strong>:&nbsp;MBA has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, GALAPAGOS, Pfizer, Sandoz, Biogen, Fresenius, Lilly, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Adacyte and TillotsPharma.</div>\\r\\n        <div>\\r\\n                    <br><strong>Keyword 1</strong>:&nbsp;Risankizumab&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 2</strong>:&nbsp;Crohn&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 3</strong>:&nbsp;Induction\\r\\n            </div>\\r\\n  \", 'Abstract Url': 'https://programme.ueg.eu/week2024/#/details/presentations/2334', 'Company': None, 'Asset': 'Risankizumab', 'Indication': 'Crohn', 'MoA': None, 'Other Keywords': None}, {'Session Date': '2024-10-14', 'Session Start Time': '08:30', 'Session End Time': '09:30', 'Session Timezone': 'CEST', 'Session Location': 'A3', 'Session Number': 80, 'Session Pathways': 'IBD', 'Session CME': 'Pfizer', 'Session Type': 'Abstract Session', 'Session Group': 3, 'Session Title': 'Ameliorating acute disease through novel treatment in IBD: Part 1', 'Session Description': None, 'Session Format': 'Live, Recording, Q&A', 'Presentation Date': '2024-10-14', 'Presentation Location': 'A3', 'Presentation Start Time': '08:54', 'Presentation End Time': '09:06', 'Presentation ID': 704, 'Presentation Number': 'OP044', 'Presentation Title': 'EXTENDED INDUCTION RESPONSE OVER TIME IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB IN THE LUCENT-1 AND -2 TRIALS', 'Presentation Title (lowercase)': 'extended induction response over time in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab in the lucent-1 and -2 trials', 'Abstract Authors': 'David T. Rubin', 'Abstract Affiliations': 'University of Chicago Medicine', 'Abstract': '<i><u>D.T. Rubin</u><sup>1</sup>, A. Charabaty<sup>2</sup>, V. Jairath<sup>3</sup>, J. Walter<sup>4</sup>, K. McGinnis<sup>5</sup>, R. Moses<sup>5</sup>, S. Maier<sup>5</sup>, R. Escobar<sup>5</sup>, S.K. Baygani<sup>5</sup>, L. Zaremba-Pechmann<sup>5</sup>, T. Kobayashi<sup>6</sup></i><br>\\r\\n<div><sup>1</sup>University of Chicago Medicine, Chicago, United States of America, <sup>2</sup>John Hopkins University, Baltimore, United States of America, <sup>3</sup>Alimentiv Inc., Gastroenterology, London, Canada, <sup>4</sup>Thomas Jefferson University Hospitals, Philadelphia, United States of America, <sup>5</sup>Eli Lilly and Company, Indianapolis, United States of America, <sup>6</sup>Kitasato University Kitasato Institute Hospital, Tokyo, Japan<br><br></div>\\r\\n\\r\\n            <div><strong>Introduction</strong>:&nbsp;The safety and efficacy of mirikizumab (miri), an anti-IL-23p19 antibody, for moderately-to-severely active ulcerative colitis (UC) have been shown in Phase 3 trials (LUCENT-1 and -2; NCT03518086, NCT03524092). Extended induction with 3 additional intravenous (IV) doses of miri induced clinical response at Week (W)24 in more than 50% of patients who did not initially achieve clinical response to induction with miri at W12. Among the clinical non-responders, some had achieved partial response at W12 (Table 1). We assessed response over time in clinical non-responders at the end of induction who received extended induction with miri for an additional 12W.</div>\\r\\n                <div><strong>Aims & Methods</strong>:&nbsp;In LUCENT-1, patients (N=1281) were randomly assigned 3:1 to receive miri 300mg or placebo IV at W0, W4, and W8. Patients not achieving clinical response with miri 300mg IV at W12 of LUCENT-1 (n=272) received extended induction treatment with open-label miri 300mg IV at W12, W16, and W20 (LUCENT-2). Symptomatic remission, symptomatic response, bowel urgency (BU) remission, and BU change from baseline at W16 and W20 are reported (definitions in Table 1) in addition to the previously disclosed outcomes at W24. For categorical variables, number and percentage of patients who are responders/remitters were presented. For continuous variables, mean change from baseline with standard deviation (SD) was used. Missing data were imputed as non-response.</div>\\r\\n                <div><strong>Results</strong>:&nbsp;Among patients who were clinical non-responders to 12W of initial induction treatment (n=272), 53 (19.5%); 73 (26.8%); 101 (37.1%) achieved symptomatic remission and 144 (52.9%); 169 (62.1%); 197 (72.4%) patients achieved symptomatic response at W16, W20, and W24, respectively. Among miri induction non-responders with Urgency Numeric Rating Scale (NRS) score ≥3 at induction baseline (n=256), 10.9% achieved BU remission at W16, 14.8% at W20, and 19.9% at W24. There was a 1.8±2.4 (mean±SD) point reduction in Urgency NRS scores at W16, 2.1±2.5 reduction at W20, and 2.5±2.7 reduction at W24 (Table 1).<br><br><table border=\"1\" cellspacing=\"0\" cellpadding=\"0\" align=\"left\" ><tbody><tr><td colspan=\"5\" valign=\"top\"><strong>Table 1. Clinical outcomes for the </strong><strong>mirikizumab induction non-responder patient population</strong></td></tr><tr><td><strong>Outcomes for miri IV extended induction</strong></td><td><strong>W12 (W0 extended induction)</strong><br><strong> </strong><br><strong>M</strong><strong>iri induction non-responders<sup>a</sup></strong><br><strong>300 miri IV, Q4W</strong><br><strong>N= 272</strong></td><td><strong>W16 (W4 extended induction)</strong><br><strong> </strong><br><strong>M</strong><strong>iri induction non-responders<sup>a</sup></strong><br><strong>300 miri IV, Q4W</strong><br><strong>N= 272</strong></td><td><strong>W20 (W8 extended induction)</strong><br><strong> </strong><br><strong>M</strong><strong>iri induction non-responders<sup>a</sup></strong><br><strong>300 miri IV, Q4W</strong><br><strong>N= 272</strong></td><td><strong>W24 (W12 extended induction)</strong><br><strong> </strong><br><strong>M</strong><strong>iri induction non-responders<sup>a</sup></strong><br><strong>300 miri IV, Q4W</strong><br><strong>N= 272</strong></td></tr><tr><td><strong>Clinical response<sup>b</sup> </strong></td><td>0</td><td>n/a</td><td>n/a</td><td>146 (53.7)</td></tr><tr><td valign=\"top\"><strong>Symptomatic remission<sup>c</sup> </strong></td><td>13 (4.8)</td><td>53 (19.5)</td><td>73 (26.8)</td><td>101 (37.1)</td></tr><tr><td valign=\"top\"><strong>Symptomatic response<sup>d</sup><sup> </sup></strong></td><td>83 (30.5)</td><td>144 (52.9)</td><td>169 (62.1)</td><td>197 (72.4)</td></tr><tr><td valign=\"top\"><strong>BU remission<sup>e</sup></strong><strong><sup> </sup></strong><strong>(Nx= 256) </strong></td><td>18 (7.0)</td><td>28 (10.9)</td><td>38 (14.8)</td><td>51 (19.9)</td></tr><tr><td valign=\"top\"><strong>BU change from baseline<sup>f</sup></strong><strong><sup> </sup></strong><strong>[mBOCF; mean (SD)]</strong></td><td>-1.2 (2.2)</td><td>-1.8 (2.4)</td><td>-2.1 (2.5)</td><td>-2.5 (2.7)</td></tr><tr><td colspan=\"5\" valign=\"top\">Data reported as n (%) unless otherwise indicated.<br><em>Abbreviations: BU=bowel urgency; IV=intravenous; mBOCF=modified baseline observation carried forward; miri=mirikizumab; N=patient population; n=patient subpopulation; Nx=number of</em><em> patients with Urgency Numeric Rating Scale ≥3 at induction baseline; Q4W= every four weeks; SD=standard deviation; W=week</em><br><sup>a</sup>The miri induction non-responder population only included patients who continued to the maintenance trial (LUCENT-2)<br><sup>b</sup>Defined as ≥2-point and ≥30% decrease in Modified Mayo Score from baseline; rectal bleeding =0 or 1 or ≥1-point decrease from baseline<br><sup>c</sup>Defined as stool frequency =0 or stool frequency =1 with ≥1-point decrease in Modified Mayo Score from baseline; rectal bleeding=0<br><sup>d</sup>Defined as at least a 30% decrease from baseline in the composite clinical endpoint of the sum of stool frequency and rectal bleeding subscores<br><sup>e</sup>Defined as Urgency Numeric Rating Scale score=0 or 1<br><sup>f</sup>Change from baseline in Urgency Numeric Rating Scale score; range 0 to 10; a lower score indicates less severe bowel urgency</td></tr></tbody></table></div>\\r\\n                <div><strong>Conclusion</strong>:&nbsp;Among patients who were clinical non-responders to induction at W12, more than 50% achieved clinical response after 3 additional induction doses with miri. A proportion of patients benefited earlier from extended induction at W16 and W20, respectively, regarding symptomatic response and remission, and BU outcomes. The results demonstrate continued symptomatic improvement and further support the potential benefit of extended induction treatment.</div>\\r\\n                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\\r\\n                <div><strong>Disclosure</strong>:&nbsp;<strong>DR </strong>receives grants or contracts from Takeda, and discloses consultancy fees with Abbvie, Altrubio, Allergan, Inc., American College of Gastroenterology, Arena Pharmaceuticals, Athos Therapeutics, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Cornerstones Health, Inc. (non-profit), GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, GoDuRn, LLC, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Eli Lilly and Company, Materia Prima, Pfizer, Prometheus Biosciences, Reistone, Takeda and Techlab, Inc.<br><strong>AC</strong> is on the advisory board of and/or a consultant for and/or receives educational grants from Abbvie, Eli Lilly and Company, Janssen, Pfizer, and Takeda.<br><strong>VJ</strong> has received consulting/advisory board fees from AbbVie, Alimentiv Inc. (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Asieris, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Reistone Biopharma, Roche, Sandoz, Takeda and TopiVert, and speaker’s fees from AbbVie, Ferring, Galapagos, Janssen, Pfizer, Shire and Takeda.<br><strong>JW </strong>has received consultancy or advisory board fees from Medtronic and Eli Lilly and Company.<br><strong>KM, RM,<sup> </sup>SM, RE, SB</strong> are employees and minor shareholders of Eli Lilly and Company<sup> </sup><br><strong>LZ-P</strong> is an employee of HaaPACS GmbH and contractor for Eli Lilly and Company<br><strong>TK</strong> has received lecture fees from Abbie GK, Activaid, Alfresa Pharma, Janssen Pharmaceutical, JIMRO, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, Pfizer Japan, Takeda Pharmaceutical, Thermo Fisher Diagnostics and Zeria Pharmaceutical; research grants from Abbvie GK, Activaid, Alfresa Pharma, Bristol Myers Squibb, Eli Lilly Japan, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceutical, JMDC, Mochida Pharmaceutical, Nippon Kayaku, Pfizer Japan and Takeda Pharmaceutical; scholarship contributions from Mitsubishi Tanabe Pharma, Nippon Kayaku and Zeria Pharmaceutical; study group sponsorship by Abbvie GK, EA Pharma, JIMRO, Kyorin Pharmaceutical, Mochida Pharmaceutical, Otsuka Holdings and Zeria Pharmaceutical; and advisory or consultancy fees from Abbie GK, Activaid, Alfresa Pharma, EA Pharma, Janssen Pharmaceutical, KISSEI Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer Japan and Takeda Pharmaceutical.</div>\\r\\n        <div>\\r\\n                    <br><strong>Keyword 1</strong>:&nbsp;Ulcerative Colitis&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 2</strong>:&nbsp;Mirikizumab&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 3</strong>:&nbsp;Extended induction response\\r\\n            </div>\\r\\n  ', 'Abstract Url': 'https://programme.ueg.eu/week2024/#/details/presentations/3369', 'Company': None, 'Asset': 'Mirikizumab', 'Indication': 'Ulcerative Colitis', 'MoA': None, 'Other Keywords': None}]\n","<i><u>D. Laharie</u><sup>1</sup>, C.A Siegel<sup>2</sup>, P.S. Dulai<sup>3</sup>, M. Katsuyoshi<sup>4</sup>, J. P. Gisbert<sup>5</sup>, K. Samaan<sup>6</sup>, I. Redondo<sup>6</sup>, S.K. Baygani<sup>6</sup>, J. Paulissen<sup>7</sup>, V. Jairath<sup>8</sup></i><br>\n","<div><sup>1</sup>CHU de Bordeaux Hopital Haut-Leveque Dept. de Gastroenterologie, Bordeaux, France, <sup>2</sup>Dartmouth-Hitchcock Medical Center, Lebanon, United States of America, <sup>3</sup>Northwestern Medicine Digestive Health Center, Chicago, United States of America, <sup>4</sup>Tokyo Medical and Dental University, Gastroenterology and Hepatology, Tokyo, Japan, <sup>5</sup>Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa [IIS-Princesa], Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas [CIBEREHD], Madrid, Spain, <sup>6</sup>Eli Lilly and Company, Indianapolis, United States of America, <sup>7</sup>Syneos Health, Morrisville, United States of America, <sup>8</sup>University of Western Ontario, London, Canada<br><br></div>\n","\n","            <div><strong>Introduction</strong>:&nbsp;Mirikizumab, an anti-IL-23p19 antibody, has demonstrated efficacy and safety in moderately-to-severely active ulcerative colitis (UC) Phase 3 trials (LUCENT-1 and -2; NCT03518086, NCT03524092). A treatment goal for patients with UC is corticosteroid (CS)-free remission. We assessed the CS-sparing effect of mirikizumab among the extended induction patient population receiving CS at induction baseline<strong >.</strong></div>\n","                <div><strong>Aims & Methods</strong>:&nbsp;In LUCENT-1, patients in the modified intention to treat mirikizumab group (n=868) received mirikizumab 300 mg intravenously (IV) at Week (W)0, W4, and W8. Patients receiving mirikizumab on CS at baseline (n=351) remained on their stable baseline dose (prednisone ≤20 mg/day or equivalent, budesonide MMX 9 mg/day, or beclomethasone 5 mg/day) during induction<strong > </strong>(W0 to W12). Patients not achieving clinical response (≥2-point and ≥30% decrease in Modified Mayo Score from baseline; and rectal bleeding=0 or 1, or ≥1-point decrease from baseline) at W12 (n=272) entered LUCENT-2 open label (OL) extended induction and received 300 mg mirikizumab IV at W12, W16, and W20. Extended induction responders at W24 (n=144) entered OL maintenance and received 200mg mirikizumab subcutaneously (SC) Q4W until W52. CS taper was initiated if clinical response was achieved at W24 or earlier based on investigator discretion if symptomatic improvement was evident. Patients who discontinued CS and remained off throughout the study were considered “discontinued.” Descriptive statistics for efficacy outcomes were summarized. Missing data were imputed as non-response.</div>\n","                <div><strong>Results</strong>:&nbsp;Of the 272 mirikizumab patients in the extended induction population, 118 received CS at induction baseline. The mean prednisone equivalent dose was 15mg. At W24, among the 62/118 (52.5%) who achieved clinical response and continued with maintenance, 8 (12.9%) discontinued CS, 2 (3.2%) achieved clinical remission off CS, and 8 (12.9%) achieved symptomatic remission off CS. At W52, 43/62 (69.4%) of the extended induction responders discontinued CS, 18 (29.0%) achieved clinical remission off CS, and 37 (59.7%) achieved symptomatic remission off CS. Among patients with non-missing data who completed W52 of mirikizumab treatment, 89.6% had discontinued CS (Table).<br><strong >Table. Corticosteroid-Sparing Effect of Mirikizumab in Extended Induction Population Receiving Corticosteroids at Induction Baseline</strong><br><table border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"100%\" ><tbody><tr><td width=\"26.53061224489796%\" rowspan=\"2\" valign=\"top\"> </td><td width=\"40.816326530612244%\" rowspan=\"2\" valign=\"top\"> </td><td width=\"32.6530612244898%\" colspan=\"2\" valign=\"top\"><strong>Mirikizumab </strong><strong>Extended Induction Responders</strong><strong><sup>a</sup> (N=62)</strong><br> </td></tr><tr><td width=\"50%\"><strong>Observed</strong><br><strong>n/Nx (%)</strong></td><td width=\"50%\"><strong>NRI</strong><br><strong>n (%)</strong></td></tr><tr><td width=\"26.53061224489796%\" rowspan=\"3\" valign=\"top\"><strong><u>Week 24</u></strong><br><strong> </strong></td><td width=\"40.816326530612244%\" valign=\"top\"><strong>Clinical remission<sup>b</sup> and off CS</strong></td><td width=\"16.3265306122449%\">2/62 (3.2)</td><td width=\"16.3265306122449%\">2 (3.2)</td></tr><tr><td width=\"55.55555555555556%\" valign=\"top\"><strong>Symptomatic remission<sup>c</sup> and off CS</strong></td><td width=\"22.22222222222222%\">8/62 (12.9)</td><td width=\"22.22222222222222%\">8 (12.9)</td></tr><tr><td width=\"55.55555555555556%\" valign=\"top\"><strong>Discontinued CS<sup>d</sup></strong></td><td width=\"22.22222222222222%\">8/53 (15.1)</td><td width=\"22.22222222222222%\">8 (12.9)</td></tr><tr><td width=\"26.53061224489796%\" rowspan=\"4\" valign=\"top\"><strong><u>Week 52</u></strong><br><strong> </strong></td><td width=\"40.816326530612244%\" valign=\"top\"><strong>Clinical remission<sup>b</sup> and off CS</strong></td><td width=\"16.3265306122449%\">18/50 (36.0)</td><td width=\"16.3265306122449%\">18 (29.0)</td></tr><tr><td width=\"55.55555555555556%\" valign=\"top\"><strong>Symptomatic remission<sup>c</sup> and off CS</strong></td><td width=\"22.22222222222222%\">37/52 (71.2)</td><td width=\"22.22222222222222%\">37 (59.7)</td></tr><tr><td width=\"55.55555555555556%\" valign=\"top\"><strong>CS-free remission<sup>e</sup></strong></td><td width=\"22.22222222222222%\">16/49 (32.7)</td><td width=\"22.22222222222222%\">16 (25.8)</td></tr><tr><td width=\"55.55555555555556%\" valign=\"top\"><strong>Discontinued CS<sup>d</sup></strong><br><strong><sup> </sup></strong></td><td width=\"22.22222222222222%\">43/48 (89.6)</td><td width=\"22.22222222222222%\">43 (69.4)</td></tr><tr><td width=\"100%\" colspan=\"4\" valign=\"top\">Abbreviations: CS=corticosteroid; N =number of patients in analysis population; n=number of patients in the specified category; NRI=non-responder imputation; Nx=number of patients with non-missing values<br><sup>a</sup> Patients without response at week 12 treated with mirikizumab extended induction and responded at week 24. Clinical response defined as ≥2-point and ≥30% decrease in Modified Mayo Score from baseline; and rectal bleeding=0 or 1, or ≥1-point decrease from baseline<br><sup>b</sup> Defined as stool frequency subscore=0 or 1 with ≥1-point decrease from induction baseline, a rectal bleeding subscore=0, and an endoscopic subscore=0 or 1 (excluding friability)<br><sup>c</sup> Defined as stool frequency subscore=0 or 1 with ≥1-point decrease from induction baseline, a rectal bleeding subscore=0<br><sup>d</sup><strong> </strong>Patients discontinued CS and remained off through Week 52<br><sup>e </sup>Clinical remission at Week 52 + symptomatic remission at Week 40 + off CS for ≥12 weeks</td></tr></tbody></table><strong  style=\"\">​</strong></div>\n","                <div><strong>Conclusion</strong>:&nbsp;Nearly 70% of extended induction responders discontinued CS by W52. CS-sparing effect of mirikizumab in patients with moderately-to-severely active UC is clinically meaningful and aligns with the treatment goal of CS discontinuation.</div>\n","                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\n","                <div><strong>Disclosure</strong>:&nbsp;<strong >DL </strong>declares counseling, boards, transports or fees from Abbvie, Biogaran, Biogen, Ferring, HAC-pharma, Janssen, MSD, Novartis, Pfizer, Prometheus, Roche, Takeda, Theradiag, Tillots.<br><strong>CS</strong> reports advisory board and consultant fees for Abbvie, BMS, Lilly, Janssen, Pfizer, Prometheus, Takeda and Trellus Health; speaker for CME activities for Abbvie, Janssen, Pfizer and Takeda; received grant support from Abbvie, Janssen, Pfizer and Takeda; intellectual property for a “System and Method of Communicating Predicted Medical Outcomes”; co-founder of MiTest Health, LLC (software company) that has technology (PROSPECT/CDPATH) that has been licensed to Takeda.<br><strong>PD</strong> reports consulting fees from Johnson and Johnson, Gilead, Lilly, BMS, Novartis, Pfizer, and Takeda; financial support for research from Takeda and Pfizer; stock options for DigbiHealth; and licensing royalties from PreciDiag. <br><strong>KM</strong> has received speaker fees and research grants from AbbVie, EA Pharma, Mochida, Mitsubishi-Tanabe, ZERIA, Nippon Kayaku, and JIMRO; speaker fees from Takeda, Janssen, Pfizer, Kyorin, Kissei, Gilead, Eli Lilly, and Celltrion Healthcare.<br><strong>JPG</strong> has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine and Vifor Pharma. <br><strong>KHS, IR,</strong><strong><sup> </sup></strong><strong>SB</strong> are employees and minor shareholders of Eli Lilly and Company<sup> </sup> <br><strong>JP</strong> is an employee of Syneos Health and contractor for Eli Lilly and Company <br><strong>VJ</strong> has received consulting/advisory board fees from AbbVie, Alimentiv Inc. (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Asieris, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Reistone Biopharma, Roche, Sandoz, Takeda and TopiVert, and speaker’s fees from AbbVie, Ferring, Galapagos, Janssen, Pfizer, Shire and Takeda.</div>\n","        <div>\n","                    <br><strong>Keyword 1</strong>:&nbsp;Ulcerative Colitis&nbsp;&nbsp;&nbsp;\n","                            <strong>Keyword 2</strong>:&nbsp;Mirikizumab&nbsp;&nbsp;&nbsp;\n","                            <strong>Keyword 3</strong>:&nbsp;Corticosteroid-sparing effect\n","            </div>\n","  \n","[{'Session Date': '2024-10-14', 'Session Start Time': '08:30', 'Session End Time': '09:30', 'Session Timezone': 'CEST', 'Session Location': 'A3', 'Session Number': 80, 'Session Pathways': 'IBD', 'Session CME': 'Pfizer', 'Session Type': 'Abstract Session', 'Session Group': 3, 'Session Title': 'Ameliorating acute disease through novel treatment in IBD: Part 1', 'Session Description': None, 'Session Format': 'Live, Recording, Q&A', 'Presentation Date': '2024-10-14', 'Presentation Location': 'A3', 'Presentation Start Time': '08:30', 'Presentation End Time': '08:42', 'Presentation ID': 702, 'Presentation Number': 'OP042', 'Presentation Title': 'EFFICACY OF GUSELKUMAB VERSUS PLACEBO IN CROHN’S DISEASE BASED ON PRIOR RESPONSE/EXPOSURE TO BIOLOGIC THERAPY: RESULTS OF THE GALAXI 2 &AMP; 3 PHASE 3 STUDIES', 'Presentation Title (lowercase)': 'efficacy of guselkumab versus placebo in crohn’s disease based on prior response/exposure to biologic therapy: results of the galaxi 2 &amp; 3 phase 3 studies', 'Abstract Authors': 'Bruce E. Sands', 'Abstract Affiliations': 'Icahn School of Medicine at Mount Sinai', 'Abstract': '<i><u>B.E. Sands</u><sup>1</sup>, G. D’Haens<sup>2</sup>, S. Danese<sup>3</sup>, T. Hisamatsu<sup>4</sup>, W. Reinisch<sup>5</sup>, N.A. Terry<sup>6</sup>, L. Salese<sup>6</sup>, R. Van Rampelbergh<sup>7</sup>, Z. Yang<sup>6</sup>, J. Johanns<sup>6</sup>, G. DuVall<sup>8</sup>, N. Abu Farsakh<sup>9</sup>, R. Panaccione<sup>10</sup></i><br>\\r\\n<div><sup>1</sup>Dr. Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States of America, <sup>2</sup>Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, Netherlands, <sup>3</sup>Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, <sup>4</sup>Department of Gastroenterology and Hepatology, Kyorin University, Tokyo, Japan, <sup>5</sup>Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria, <sup>6</sup>Janssen Research & Development, LLC, Spring House, United States of America, <sup>7</sup>Janssen Research & Development, Antwerp, Belgium, <sup>8</sup>Tyler Research Institute, LLC, Tyler, United States of America, <sup>9</sup>King Abdullah University Hospital, Irbid, Jordan, <sup>10</sup>Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Canada<br><br></div>\\r\\n\\r\\n            <div><strong>Introduction</strong>:&nbsp;GALAXI 2 &amp; 3 are identically designed 48-week, randomized, double-blind, double-dummy, placebo (PBO)- and active-comparator, treat-through registrational trials assessing the efficacy and safety of IV induction and SC maintenance therapy with guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, in participants (pts) with moderately to severely active Crohn’s disease (CD). Primary results of each study were previously reported; here we explore the impact of biologic therapy exposure on efficacy outcomes with GUS compared to PBO in the pooled GALAXI 2 &amp; 3 dataset.</div>\\r\\n                <div><strong>Aims & Methods</strong>:&nbsp;Pts with inadequate response or intolerance to conventional therapy or biologic therapy (BIO-ir), active CD (CDAI 220–450 + mean daily SF&gt;3 or AP&gt;1), and SES-CD≥6 (≥4 for isolated ileal disease) were randomly assigned 2:2:2:1 at week (Wk) 0 to GUS 200mg IV q4w (x3)→100mg SC q8w, GUS 200mg IV q4w (x3)→200mg SC q4w, UST IV→SC, or PBO. In each trial, the composite co-primary endpoints were 1) clinical response at Wk12 + clinical remission at Wk48, and 2) clinical response at Wk12 + endoscopic response at Wk48, comparing each GUS regimen to PBO. Major secondary endpoints included clinical remission at Wk12 and endoscopic response at Wk12. Analyses of BIO-ir and BIO-naïve subgroups in the individual trials were prespecified; pooled analyses were performed post hoc.</div>\\r\\n                <div><strong>Results</strong>:&nbsp;\\u200bIn the pooled dataset, 52% (378/730) of pts randomized to PBO or GUS had a prior history of BIO-ir and 42% (305/730) were BIO-naïve (6% [47/730] had prior exposure to biologics but no documented failure). At Wk12, GUS achieved higher rates of clinical remission and endoscopic response compared to PBO in the overall population and BIO-ir and BIO-naïve subgroups (<strong>Table</strong>). For the composite co-primary endpoints, both GUS regimens also achieved higher rates of 1) clinical response at Wk12 + clinical remission at Wk48 and 2) clinical response at Wk12 + endoscopic response at Wk48 compared to PBO in the overall population and BIO-ir and BIO-naïve subgroups.<br><br><table style=\"width: 100%; margin-left: calc(0%);\" class=\"\"><tbody><tr><td style=\"width: 100%;\" colspan=\"10\" class=\"fr-selected-cell\"><strong>Ta</strong><strong>ble. Efficacy of guselkumab (GUS) and placebo (PBO) for short- and long-term clinical and endoscopic endpoints in all participants and BIO-ir and BIO-naïve subgroups in the pooled GALAXI 2 &amp; 3 dataset</strong><br></td></tr><tr><td style=\"width: 10.0069%;\" class=\"\"><br></td><td style=\"width: 30%; text-align: center;\" colspan=\"3\"><strong>Overall population</strong><br></td><td style=\"width: 29.9523%; text-align: center;\" colspan=\"3\"><strong>Participants with a history of inadequate response or intolerance to at least 1 prior biologic<sup>a</sup> (BIO-ir)</strong><br></td><td style=\"width: 30%; text-align: center;\" colspan=\"3\"><strong>Participants with no history of exposure to biologics<sup>a</sup> (BIO-naïve) </strong><br></td></tr><tr><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239);\" class=\"\"><br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=148<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=582<br></td><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=78<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=300<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=61<br></td><td style=\"width: 20%; background-color: rgb(239, 239, 239); text-align: center;\" colspan=\"2\"><strong>GUS 200mg IV combined</strong><sup><strong>b</strong></sup><br>N=244<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical remission at Wk12</strong><br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\">28 (18.9%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">274 (47.1%)<br><strong>∆ 28.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">15 (19.2%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">138 (46.0%)<br><strong>∆ 26.9%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">10 (16.4%)<br></td><td style=\"width: 20%; text-align: center;\" colspan=\"2\">121 (49.6%)<br><strong>∆ 32.1%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Endoscopic response at Wk12</strong><br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">18 (12.2%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">215 (36.9%)<br><strong>∆ 25.2%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">5 (6.4%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">87 (29.0%)<br><strong>∆ 22.6%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">11 (18.0%)<br></td><td style=\"width: 20.0136%; text-align: center;\" colspan=\"2\">113 (46.3%)<br><strong>∆ 27.7%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239);\" class=\"\"><br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=148<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=286<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=296<br></td><td style=\"width: 10.0068%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=78<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=153<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=147<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>PBO</strong><br>N=61<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 100mg</strong><sup><strong>c</strong></sup><br>N=116<br></td><td style=\"width: 10%; background-color: rgb(239, 239, 239); text-align: center;\"><strong>GUS 200mg</strong><sup><strong>d</strong></sup><br>N=128<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical response at Wk12 + clinical remission at Wk48<br></strong>(composite co-primary endpoint)<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">18 (12.2%)<br></td><td style=\"width: 10%; text-align: center;\">137 (47.9%)<br><strong>∆ 35.8%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">152 (51.4%)<br><strong>∆ 39.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">10 (12.8%)<br></td><td style=\"width: 10%; text-align: center;\">70 (45.8%)<br><strong>∆ 33.2%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">73 (49.7%)<br><strong>∆ 37.4%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">7 (11.5%)<br></td><td style=\"width: 10%; text-align: center;\">60 (51.7%)<br><strong>∆ 40.4%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">70 (54.7%)<br><strong>∆ 41.8%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 10.0068%;\"><strong>Clinical response at Wk12 + endoscopic response at Wk48</strong><br>(composite co-primary endpoint)<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">8 (5.4%)<br></td><td style=\"width: 10%; text-align: center;\">104 (36.4%)<br><strong>∆ 30.7%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">110 (37.2%)<br><strong>∆ 31.8%</strong><br>P&lt;.001*<br></td><td style=\"width: 10.0068%; text-align: center; vertical-align: middle;\" class=\"\">4 (5.1%)<br></td><td style=\"width: 10%; text-align: center;\">55 (35.9%)<br><strong>∆ 30.9%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">46 (31.3%)<br><strong>∆ 26.7%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center; vertical-align: middle;\" class=\"\">4 (6.6%)<br></td><td style=\"width: 10%; text-align: center;\">47 (40.5%)<br><strong>∆ 33.0%</strong><br>P&lt;.001*<br></td><td style=\"width: 10%; text-align: center;\">56 (43.8%)<br><strong>∆ 36.5%</strong><br>P&lt;.001*<br></td></tr><tr><td style=\"width: 100%;\" colspan=\"10\">Data are presented as n (%); ∆% (adjusted treatment difference) vs PBO; p-value vs PBO.<br>Adjusted treatment differences and p-values were based on the common risk difference by use of Mantel-Haenszel stratum weights and the Sato variance estimator. The stratification variables used are baseline CDAI score (≤300 or &gt;300), baseline SES-CD score (≤12 or &gt;12), BIO-ir status (Yes or No; this variable used only in analyses of the overall population), and baseline corticosteroid use (Yes or No). Population N values reflect the primary analysis set, defined as all randomized participants who received at least 1 (partial or complete) dose of study intervention and had a screening SES-CD score ≥6 (or ≥4 for participants with isolated ileal disease). PBO pts not in clinical response at week (Wk) 12 switched to UST.<br><br><u>Endpoint definitions</u>: clinical remission, CDAI &lt; 150; endoscopic response, ≥50% improvement from baseline in SES-CD or SES-CD ≤ 2; clinical response, ≥100-point reduction from baseline in CDAI or CDAI &lt; 150. Participants with treatment failure or missing data were considered to not have met the endpoint.<br><br>a. Anti-TNF agents or vedolizumab<br>b. Participants assigned to either GUS 200mg IV every 4 weeks (q4w) (x3)→100mg SC q8w or GUS 200mg IV q4w (x3)→200mg SC q4w. At the Wk 12 assessment, GUS participants had only received GUS IV.<br>c. Participants assigned to GUS 200mg IV q4w (x3)→100mg SC q8w<br>d.<sup> </sup>Participants assigned to GUS 200mg IV q4w (x3)→200mg SC q4w<br>* Nominal p-value<br></td></tr></tbody></table></div>\\r\\n                <div><strong>Conclusion</strong>:&nbsp;In pooled analyses of the double-blind GALAXI 2 &amp; 3 trials, GUS was efficacious versus PBO in pts with CD regardless of prior biologic therapy exposure in both short-term (Wk12) endpoints and long-term (Wk12 + Wk48) composite endpoints.</div>\\r\\n                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\\r\\n                <div><strong>Disclosure</strong>:&nbsp;<strong >Bruce E. Sands</strong> reports potential conflicts of interest with AbbVie, Abivax, Adiso Therapeutics, Agomab, Alimentiv, Amgen, AnaptysBio, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celgene, Celltrion, ClostraBio, Equillium, Enthera, Evommune, Ferring, Fresenius Kabi, Galapagos, Genentech (Roche), Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Index Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Janssen, Kaleido, Kallyope, Lilly, Merck, Microbiotica, Mobius Care, Morphic Therapeutics, MRM Health, Pfizer, Nexus Therapeutics, Nimbus Discovery, Odyssey, Therapeutics, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Rasayana Therapeutics, Recludix Therapeutics, Reistone Biotherapeutics, Sun Pharma, Surrozen, Target RWE, Takeda, Teva, Theravance Biopharma, TLL Pharmaceutical, TR1X, Union Therapeutics and Ventyx Biosciences.<br><strong>Geert D’Haens</strong> reports potential conflicts of interest with AbbVie, Agomab, Alimentiv, AstraZeneca, AMT, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom, Galapagos, GlaxoSmithKline, Gossamerbio, Immunic, Index, Johnson &amp; Johnson, Kaleido, Origo, Pfizer, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity, and Protagonist Therapeutics Inc., Seres Health, and Takeda.<br><strong>Silvio Danese</strong> reports potential conflicts of interest with AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring, Gilead, Hospira, Inotrem, Janssen, Johnson &amp; Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity, Takeda, TiGenix, UCB, and Vifor.<br><strong>Tadakazu Hisamatsu</strong> reports potential conflicts of interest with AbbVie, Bristol Myers Squibb, Daiichi-Sankyo, EA Pharma Co, Ltd., Eli Lilly, Gilead Sciences, Janssen Research &amp; Development, LLC., JIMRO, Kissei Pharmaceutical Co, Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Inc., and Takeda Pharmaceutical Co., Ltd.<br><strong>Walter Reinisch</strong> reports potential conflicts of interest with AbbVie, Aesca, Agomab, Algernon, AltruBio, Amgen, AM, AMT, AOP Orphan, Aptalis, Arena, Astellas, AstraZeneca, Avaxia, Roland Berger, Bioclinica, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Calyx, Cellerix, Chemocentryx, Celgene, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest &amp; Young, Falk, Ferring, Fresenius, Galapagos, Gatehouse, Genentech, Gilead, Grünenthal, ICON, Immundiagnostik, Index, Inova, Intrinsic Imaging, Janssen, Johnson &amp; Johnson, Kyowa Hakko Kirin, Landos, Lipid, LivaNova, Mallinckrodt, Medahead, Medice, MedImmune, Millenium, Mitsubishi Tanabe, MSD, Nash, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pfizer, Pharmacosmos, PLS Education, Procter &amp; Gamble, Prometheus, Protagonist, Provention, Quell, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres, Setpointmedical, Sigmoid, Sublimity, Takeda, Teva, Therakos, Theravance, Tigenix, UCB, Vifor, Yakult, Zealand, Zyngenia, and 4SC.<br><strong>Natalie A. Terry</strong>, <strong>Leonardo Salese</strong>, <strong>Rian Van Rampelbergh</strong>, <strong>Zijiang Yang</strong>, and <strong>Jewel Johanns</strong> are employees of Janssen Research &amp; Development (a Johnson &amp; Johnson Company) and may own company stock/stock options.<br><strong>George DuVall</strong> reports potential conflicts of interest with Janssen.<br><strong>Niazy Abu Farsakh</strong><strong> </strong>reports potential conflicts of interest with Abbott, Amgen, Antanea medical services, Ferring, Hikma, Janssen, and Pfizer.<br><strong>Remo Panaccione </strong>reports potential conflicts of interest with Abbivax, Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus, Viatris, Ventyx, and UCB.</div>\\r\\n        <div>\\r\\n                    <br><strong>Keyword 1</strong>:&nbsp;Crohn\\'s disease&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 2</strong>:&nbsp;guselkumab&nbsp;&nbsp;&nbsp;\\r\\n                    </div>\\r\\n  ', 'Abstract Url': 'https://programme.ueg.eu/week2024/#/details/presentations/1077', 'Company': None, 'Asset': 'Guselkumab', 'Indication': 'Crohn', 'MoA': None, 'Other Keywords': None}, {'Session Date': '2024-10-14', 'Session Start Time': '08:30', 'Session End Time': '09:30', 'Session Timezone': 'CEST', 'Session Location': 'A3', 'Session Number': 80, 'Session Pathways': 'IBD', 'Session CME': 'Pfizer', 'Session Type': 'Abstract Session', 'Session Group': 3, 'Session Title': 'Ameliorating acute disease through novel treatment in IBD: Part 1', 'Session Description': None, 'Session Format': 'Live, Recording, Q&A', 'Presentation Date': '2024-10-14', 'Presentation Location': 'A3', 'Presentation Start Time': '08:42', 'Presentation End Time': '08:54', 'Presentation ID': 703, 'Presentation Number': 'OP043', 'Presentation Title': 'REAL-WORLD SHORT-TERM EFFECTIVENESS OF RISANKIZUMAB IN REFRACTORY CROHN’S DISEASE: RISANCROHN STUDY FROM THE ENEIDA REGISTRY', 'Presentation Title (lowercase)': 'real-world short-term effectiveness of risankizumab in refractory crohn’s disease: risancrohn study from the eneida registry', 'Abstract Authors': 'Manuel Barreiro de Acosta', 'Abstract Affiliations': 'Health Research Institute of Santiago de Compostela (IDIS)', 'Abstract': \"<i><u>M. Barreiro-de Acosta</u><sup>1,2</sup>, L. Nieto-Garcia<sup>2</sup>, M. Poncela<sup>3</sup>, C.J. Gargallo-Puyuelo<sup>4</sup>, F. Rodriguez-Moranta<sup>5</sup>, D. Ceballos<sup>6</sup>, M.I. Calvo Moya<sup>7</sup>, S. Garcia-Lopez<sup>8</sup>, M. Aguas<sup>9</sup>, L. Zabalza<sup>10</sup>, C. Martinez Cuevas<sup>11</sup>, R. de Francisco<sup>12</sup>, I. Bastón-Rey<sup>1,13</sup>, F. Bermejo<sup>14</sup>, L. Madero<sup>15</sup>, M.D. Martín-Arranz<sup>16</sup>, M. Rivero<sup>17</sup>, I. Alonso-Abreu<sup>18</sup>, P. Varela Trastoy<sup>19</sup>, M.L. De Castro Parga<sup>20</sup>, B. Camps<sup>21</sup>, C. Martinez Pascual<sup>22</sup>, B. Sicilia<sup>23</sup>, J.P. Gisbert<sup>24</sup>, M. Piqueras<sup>25</sup>, C. Abril<sup>26</sup>, E. Brunet<sup>27</sup>, A. Hernandez Camba<sup>28</sup>, P. Fradejas<sup>29</sup>, Á. Ponferrada-Díaz<sup>30</sup>, M. Mañosa Ciria<sup>31</sup>, M. Algara San Nicolas<sup>32</sup>, J. Castro Poceiro<sup>33</sup>, J.A. Ferrer<sup>34</sup>, E. Ricart<sup>35</sup>, A. Elorza<sup>36</sup>, M.F. García Sepulcre<sup>37</sup>, P. Robledo<sup>38</sup>, M. Teller<sup>39</sup>, E. Sesé<sup>40</sup>, D. Busquets Casals<sup>41</sup>, F. Mesonero Gismero<sup>42</sup>, R. Pajares<sup>43</sup>, L. Bujanda Fernández de Piérola<sup>44</sup>, C. González-Muñoza<sup>45</sup>, D. Martin Rodriguez<sup>46</sup>, M.T. Diz-Lois Palomares<sup>47</sup>, I. Nicolas<sup>48</sup>, E. Domenech<sup>31</sup>, R. Ferreiro-Iglesias<sup>1,2</sup>, ENEIDA project of GETECCU</i><br>\\r\\n<div><sup>1</sup>Complexo Hospitalario Universitario de Santiago, Gastroenterology, Santiago, Spain, <sup>2</sup>Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Santiago de Compostela, Spain, <sup>3</sup>Hospital General Universitario Gregorio Marañón.Instituto de Investigación Biomédica Gregorio Marañón (IiSGM), Madrid, Spain, <sup>4</sup>Hospital Clínico Universitario “Lozano Blesa”, IIS Aragón and CIBERehd, Zaragoza, Spain, <sup>5</sup>Hospital Universitario de Bellvitge, IDIBELL, Gastroenterology, Barcelona, Spain, <sup>6</sup>Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain, <sup>7</sup>Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology, Madrid, Spain, <sup>8</sup>Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain, <sup>9</sup>La Fe Universitary And Politecnic Hospital, Gastroenterology Unit, Valencia, Spain, <sup>10</sup>Hospital Universitario de Navarra, Gastroenterology, Pamplona, Spain, <sup>11</sup>Hospital Universitario Rio Hortega, Valladolid, Spain, <sup>12</sup>Hospital Universitario Central de Asturias and ISPA, Gastroenterology, Oviedo, Spain, <sup>13</sup>Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Santiago de CompostelaSsps, Spain, <sup>14</sup>H Fuenlabrada, Gastroenterology, Fuenlabrada, Spain, <sup>15</sup>Hospital General Universitario de Alicante and CIBERehd, Gastroenterology, Alicante, Spain, <sup>16</sup>Hospital La Paz, Gastroenterology, Madrid, Spain, <sup>17</sup>Marqués de Valdecilla Universitary Hospital, Gastroenterology, Santander, Spain, <sup>18</sup>Hospital Universitario de Canarias (H.U.C.), Santa Cruz de Tenerife, Spain, <sup>19</sup>Hospital de Cabueñes, Gijon, Spain, <sup>20</sup>Hospital Álvaro Cunqueiro, Estrutura Organizativa de Xestión Integrada de Vigo, Gastroenterology, Vigo, Spain, <sup>21</sup>Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Gastroenterology, Barcelona, Spain, <sup>22</sup>H.C.U.Virgen de la Arrixaca, Gastroenterology, Murcia, Spain, <sup>23</sup>Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain, <sup>24</sup>Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Gastroenterology, Madrid, Spain, <sup>25</sup>Consorci Sanitari Terrasa, Gastroenterology, Barcelona, Spain, <sup>26</sup>Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain, <sup>27</sup>Parc Tauli, Digestive, Sabadell, Spain, <sup>28</sup>Complejo Hospitalario Universitario Ntra. Sra. de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain, <sup>29</sup>Complejo Asistencial de Zamora, Gastroenterology, Zamora, Spain, <sup>30</sup>Hospital Infanta Leonor, Madrid, Spain, <sup>31</sup>Hospital Universitari Germans Trias I Pujol and CIBEREHD, Gastroenterology, Badalona, Spain, <sup>32</sup>H.12 Octubre, Madrid, Spain, <sup>33</sup>Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology, Barcelona, Spain, <sup>34</sup>Hospital Fundacion Alcorcon, Gastroenterology, Alcorcon, Spain, <sup>35</sup>Hospital Clínic i Provincial, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Gastroenterology, Barcelona, Spain, <sup>36</sup>Hospital de Galdakao-Usansolo, Gastroenterology, Galdakao, Spain, <sup>37</sup>Hospital General Universitario de Elche, Gastroenterology, Elche, Spain, <sup>38</sup>Hospital Universitario de Cáceres, Caceres, Spain, <sup>39</sup>Althaia Xarxa Assistencial universitaria de Manresa, Gastroenterology, Manresa, Spain, <sup>40</sup>Hospital Universitario Arnau de Vilanova, Gastroenterology, Lleida, Spain, <sup>41</sup>H. DE GIRONA DR. J. TRUETA/ICO GERONA, Gastroenterology, Girona, Spain, <sup>42</sup>Hospital Ramon y Cajal, Gastroenterology, Madrid, Spain, <sup>43</sup>Hospital Universitario Infanta Sofía, Gastroenterology, Madrid, Spain, <sup>44</sup>Hospital Universitario Donostia and  Biodonostia, San Sebastián, Spain, <sup>45</sup>Hospital Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, <sup>46</sup>Hospital Infanta Cristina, Madrid, Spain, <sup>47</sup>Hospital Universitario A Coruña, Gastroenterology, A Coruña, Spain, <sup>48</sup>Hospital General Universitario Reina Sofía, Gastroenterology, Murcia, Spain<br><br></div>\\r\\n\\r\\n            <div><strong>Introduction</strong>:&nbsp;Phase III trials have demonstrated the efficacy of risankizumab (RZB), this being the first humanised monoclonal IgG1 antibody which targets the interleukin 23 p19 subunit, in moderate-to-severe Crohn's disease (CD). However, real-world data in induction with this drug is scarce. The aim of the study was to assess the real-world short-term effectiveness and safety of RZB in multi-refractory patients with CD.</div>\\r\\n                <div><strong>Aims & Methods</strong>:&nbsp;Adult CD patients that had received induction doses with RZB in the ENEIDA registry—a large prospectively maintained Spanish database promoted by the Spanish Working Group in Crohn’s and Colitis (GETECCU)— were included. Clinical and demographical data including number of previous biologics and advanced therapies were included. The primary endpoint was steroid-free clinical remission evaluated at any point between weeks 8 and 12 (Harvey-Bradshaw [HB] score &lt;5). Secondary endpoints included steroid free clinical remission at the end of follow-up, clinical, biochemical improvement (C-reactive protein (CRP) and/or faecal calprotectine (FC)), need for CD-related surgery and adverse events related with the drug. The data are presented as median (range), and frequencies and percentages. Statistical analysis was performed using the Chi-square or Fisher's test, and the Student-<em >t</em> test or U-Mann-Whitney test as appropriate.</div>\\r\\n                <div><strong>Results</strong>:&nbsp;417 CD patients (52% male) were included: median age was 50 (18-84) years, median disease duration 14 years, 27% were smokers. Regarding Montreal classification, 49% were L1, 10% L2, and 38% L3. Most of the patients presented inflammatory pattern (47%), 32% presented structuring, 21% penetrating behavior and perianal disease was present in 24%. 48% had abdominal CD surgery and 41% presented extraintestinal manifestations. Only 8% received concomitant immunossupressives with RZB. Regarding previous exposure to biologics or JAK inhibitors, only 3% were naïve, 49% had been exposed to 1-2 advanced therapies and 48% to 3 or more biologics or JAKs. After induction 58% of the patients achieved steroid-free clinical remission and at the end of the follow-up steroid-free clinical remission was observed in 62% of the patients. Median FC decreased from week 530 μg/g (week 0) to 333 μg/g after induction (p &lt;0.001). Regarding CRP, this decreased from median 7 mg/L at week 0 to 4.7 mg/L after induction (p = 0.002). 15 patients (3.5%) underwent intestinal resection. 23 patients (5.5%) presented adverse events including 6 infections.</div>\\r\\n                <div><strong>Conclusion</strong>:&nbsp;This is the largest cohort study of real-world data with RZB, and it includes highly refractory patients with CD and multiple prior drug failures. RZB induction provided a steroid-free clinical remission in nearly 60% of patients and a significative improvement in biomarkers. Safety was consistent with the known profile of RZB in previous trials.</div>\\r\\n                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\\r\\n                <div><strong>Disclosure</strong>:&nbsp;MBA has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, GALAPAGOS, Pfizer, Sandoz, Biogen, Fresenius, Lilly, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Adacyte and TillotsPharma.</div>\\r\\n        <div>\\r\\n                    <br><strong>Keyword 1</strong>:&nbsp;Risankizumab&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 2</strong>:&nbsp;Crohn&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 3</strong>:&nbsp;Induction\\r\\n            </div>\\r\\n  \", 'Abstract Url': 'https://programme.ueg.eu/week2024/#/details/presentations/2334', 'Company': None, 'Asset': 'Risankizumab', 'Indication': 'Crohn', 'MoA': None, 'Other Keywords': None}, {'Session Date': '2024-10-14', 'Session Start Time': '08:30', 'Session End Time': '09:30', 'Session Timezone': 'CEST', 'Session Location': 'A3', 'Session Number': 80, 'Session Pathways': 'IBD', 'Session CME': 'Pfizer', 'Session Type': 'Abstract Session', 'Session Group': 3, 'Session Title': 'Ameliorating acute disease through novel treatment in IBD: Part 1', 'Session Description': None, 'Session Format': 'Live, Recording, Q&A', 'Presentation Date': '2024-10-14', 'Presentation Location': 'A3', 'Presentation Start Time': '08:54', 'Presentation End Time': '09:06', 'Presentation ID': 704, 'Presentation Number': 'OP044', 'Presentation Title': 'EXTENDED INDUCTION RESPONSE OVER TIME IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB IN THE LUCENT-1 AND -2 TRIALS', 'Presentation Title (lowercase)': 'extended induction response over time in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab in the lucent-1 and -2 trials', 'Abstract Authors': 'David T. Rubin', 'Abstract Affiliations': 'University of Chicago Medicine', 'Abstract': '<i><u>D.T. Rubin</u><sup>1</sup>, A. Charabaty<sup>2</sup>, V. Jairath<sup>3</sup>, J. Walter<sup>4</sup>, K. McGinnis<sup>5</sup>, R. Moses<sup>5</sup>, S. Maier<sup>5</sup>, R. Escobar<sup>5</sup>, S.K. Baygani<sup>5</sup>, L. Zaremba-Pechmann<sup>5</sup>, T. Kobayashi<sup>6</sup></i><br>\\r\\n<div><sup>1</sup>University of Chicago Medicine, Chicago, United States of America, <sup>2</sup>John Hopkins University, Baltimore, United States of America, <sup>3</sup>Alimentiv Inc., Gastroenterology, London, Canada, <sup>4</sup>Thomas Jefferson University Hospitals, Philadelphia, United States of America, <sup>5</sup>Eli Lilly and Company, Indianapolis, United States of America, <sup>6</sup>Kitasato University Kitasato Institute Hospital, Tokyo, Japan<br><br></div>\\r\\n\\r\\n            <div><strong>Introduction</strong>:&nbsp;The safety and efficacy of mirikizumab (miri), an anti-IL-23p19 antibody, for moderately-to-severely active ulcerative colitis (UC) have been shown in Phase 3 trials (LUCENT-1 and -2; NCT03518086, NCT03524092). Extended induction with 3 additional intravenous (IV) doses of miri induced clinical response at Week (W)24 in more than 50% of patients who did not initially achieve clinical response to induction with miri at W12. Among the clinical non-responders, some had achieved partial response at W12 (Table 1). We assessed response over time in clinical non-responders at the end of induction who received extended induction with miri for an additional 12W.</div>\\r\\n                <div><strong>Aims & Methods</strong>:&nbsp;In LUCENT-1, patients (N=1281) were randomly assigned 3:1 to receive miri 300mg or placebo IV at W0, W4, and W8. Patients not achieving clinical response with miri 300mg IV at W12 of LUCENT-1 (n=272) received extended induction treatment with open-label miri 300mg IV at W12, W16, and W20 (LUCENT-2). Symptomatic remission, symptomatic response, bowel urgency (BU) remission, and BU change from baseline at W16 and W20 are reported (definitions in Table 1) in addition to the previously disclosed outcomes at W24. For categorical variables, number and percentage of patients who are responders/remitters were presented. For continuous variables, mean change from baseline with standard deviation (SD) was used. Missing data were imputed as non-response.</div>\\r\\n                <div><strong>Results</strong>:&nbsp;Among patients who were clinical non-responders to 12W of initial induction treatment (n=272), 53 (19.5%); 73 (26.8%); 101 (37.1%) achieved symptomatic remission and 144 (52.9%); 169 (62.1%); 197 (72.4%) patients achieved symptomatic response at W16, W20, and W24, respectively. Among miri induction non-responders with Urgency Numeric Rating Scale (NRS) score ≥3 at induction baseline (n=256), 10.9% achieved BU remission at W16, 14.8% at W20, and 19.9% at W24. There was a 1.8±2.4 (mean±SD) point reduction in Urgency NRS scores at W16, 2.1±2.5 reduction at W20, and 2.5±2.7 reduction at W24 (Table 1).<br><br><table border=\"1\" cellspacing=\"0\" cellpadding=\"0\" align=\"left\" ><tbody><tr><td colspan=\"5\" valign=\"top\"><strong>Table 1. Clinical outcomes for the </strong><strong>mirikizumab induction non-responder patient population</strong></td></tr><tr><td><strong>Outcomes for miri IV extended induction</strong></td><td><strong>W12 (W0 extended induction)</strong><br><strong> </strong><br><strong>M</strong><strong>iri induction non-responders<sup>a</sup></strong><br><strong>300 miri IV, Q4W</strong><br><strong>N= 272</strong></td><td><strong>W16 (W4 extended induction)</strong><br><strong> </strong><br><strong>M</strong><strong>iri induction non-responders<sup>a</sup></strong><br><strong>300 miri IV, Q4W</strong><br><strong>N= 272</strong></td><td><strong>W20 (W8 extended induction)</strong><br><strong> </strong><br><strong>M</strong><strong>iri induction non-responders<sup>a</sup></strong><br><strong>300 miri IV, Q4W</strong><br><strong>N= 272</strong></td><td><strong>W24 (W12 extended induction)</strong><br><strong> </strong><br><strong>M</strong><strong>iri induction non-responders<sup>a</sup></strong><br><strong>300 miri IV, Q4W</strong><br><strong>N= 272</strong></td></tr><tr><td><strong>Clinical response<sup>b</sup> </strong></td><td>0</td><td>n/a</td><td>n/a</td><td>146 (53.7)</td></tr><tr><td valign=\"top\"><strong>Symptomatic remission<sup>c</sup> </strong></td><td>13 (4.8)</td><td>53 (19.5)</td><td>73 (26.8)</td><td>101 (37.1)</td></tr><tr><td valign=\"top\"><strong>Symptomatic response<sup>d</sup><sup> </sup></strong></td><td>83 (30.5)</td><td>144 (52.9)</td><td>169 (62.1)</td><td>197 (72.4)</td></tr><tr><td valign=\"top\"><strong>BU remission<sup>e</sup></strong><strong><sup> </sup></strong><strong>(Nx= 256) </strong></td><td>18 (7.0)</td><td>28 (10.9)</td><td>38 (14.8)</td><td>51 (19.9)</td></tr><tr><td valign=\"top\"><strong>BU change from baseline<sup>f</sup></strong><strong><sup> </sup></strong><strong>[mBOCF; mean (SD)]</strong></td><td>-1.2 (2.2)</td><td>-1.8 (2.4)</td><td>-2.1 (2.5)</td><td>-2.5 (2.7)</td></tr><tr><td colspan=\"5\" valign=\"top\">Data reported as n (%) unless otherwise indicated.<br><em>Abbreviations: BU=bowel urgency; IV=intravenous; mBOCF=modified baseline observation carried forward; miri=mirikizumab; N=patient population; n=patient subpopulation; Nx=number of</em><em> patients with Urgency Numeric Rating Scale ≥3 at induction baseline; Q4W= every four weeks; SD=standard deviation; W=week</em><br><sup>a</sup>The miri induction non-responder population only included patients who continued to the maintenance trial (LUCENT-2)<br><sup>b</sup>Defined as ≥2-point and ≥30% decrease in Modified Mayo Score from baseline; rectal bleeding =0 or 1 or ≥1-point decrease from baseline<br><sup>c</sup>Defined as stool frequency =0 or stool frequency =1 with ≥1-point decrease in Modified Mayo Score from baseline; rectal bleeding=0<br><sup>d</sup>Defined as at least a 30% decrease from baseline in the composite clinical endpoint of the sum of stool frequency and rectal bleeding subscores<br><sup>e</sup>Defined as Urgency Numeric Rating Scale score=0 or 1<br><sup>f</sup>Change from baseline in Urgency Numeric Rating Scale score; range 0 to 10; a lower score indicates less severe bowel urgency</td></tr></tbody></table></div>\\r\\n                <div><strong>Conclusion</strong>:&nbsp;Among patients who were clinical non-responders to induction at W12, more than 50% achieved clinical response after 3 additional induction doses with miri. A proportion of patients benefited earlier from extended induction at W16 and W20, respectively, regarding symptomatic response and remission, and BU outcomes. The results demonstrate continued symptomatic improvement and further support the potential benefit of extended induction treatment.</div>\\r\\n                                            <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\\r\\n                <div><strong>Disclosure</strong>:&nbsp;<strong>DR </strong>receives grants or contracts from Takeda, and discloses consultancy fees with Abbvie, Altrubio, Allergan, Inc., American College of Gastroenterology, Arena Pharmaceuticals, Athos Therapeutics, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Cornerstones Health, Inc. (non-profit), GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, GoDuRn, LLC, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Eli Lilly and Company, Materia Prima, Pfizer, Prometheus Biosciences, Reistone, Takeda and Techlab, Inc.<br><strong>AC</strong> is on the advisory board of and/or a consultant for and/or receives educational grants from Abbvie, Eli Lilly and Company, Janssen, Pfizer, and Takeda.<br><strong>VJ</strong> has received consulting/advisory board fees from AbbVie, Alimentiv Inc. (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Asieris, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Reistone Biopharma, Roche, Sandoz, Takeda and TopiVert, and speaker’s fees from AbbVie, Ferring, Galapagos, Janssen, Pfizer, Shire and Takeda.<br><strong>JW </strong>has received consultancy or advisory board fees from Medtronic and Eli Lilly and Company.<br><strong>KM, RM,<sup> </sup>SM, RE, SB</strong> are employees and minor shareholders of Eli Lilly and Company<sup> </sup><br><strong>LZ-P</strong> is an employee of HaaPACS GmbH and contractor for Eli Lilly and Company<br><strong>TK</strong> has received lecture fees from Abbie GK, Activaid, Alfresa Pharma, Janssen Pharmaceutical, JIMRO, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, Pfizer Japan, Takeda Pharmaceutical, Thermo Fisher Diagnostics and Zeria Pharmaceutical; research grants from Abbvie GK, Activaid, Alfresa Pharma, Bristol Myers Squibb, Eli Lilly Japan, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceutical, JMDC, Mochida Pharmaceutical, Nippon Kayaku, Pfizer Japan and Takeda Pharmaceutical; scholarship contributions from Mitsubishi Tanabe Pharma, Nippon Kayaku and Zeria Pharmaceutical; study group sponsorship by Abbvie GK, EA Pharma, JIMRO, Kyorin Pharmaceutical, Mochida Pharmaceutical, Otsuka Holdings and Zeria Pharmaceutical; and advisory or consultancy fees from Abbie GK, Activaid, Alfresa Pharma, EA Pharma, Janssen Pharmaceutical, KISSEI Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer Japan and Takeda Pharmaceutical.</div>\\r\\n        <div>\\r\\n                    <br><strong>Keyword 1</strong>:&nbsp;Ulcerative Colitis&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 2</strong>:&nbsp;Mirikizumab&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 3</strong>:&nbsp;Extended induction response\\r\\n            </div>\\r\\n  ', 'Abstract Url': 'https://programme.ueg.eu/week2024/#/details/presentations/3369', 'Company': None, 'Asset': 'Mirikizumab', 'Indication': 'Ulcerative Colitis', 'MoA': None, 'Other Keywords': None}, {'Session Date': '2024-10-14', 'Session Start Time': '08:30', 'Session End Time': '09:30', 'Session Timezone': 'CEST', 'Session Location': 'A3', 'Session Number': 80, 'Session Pathways': 'IBD', 'Session CME': 'Pfizer', 'Session Type': 'Abstract Session', 'Session Group': 3, 'Session Title': 'Ameliorating acute disease through novel treatment in IBD: Part 1', 'Session Description': None, 'Session Format': 'Live, Recording, Q&A', 'Presentation Date': '2024-10-14', 'Presentation Location': 'A3', 'Presentation Start Time': '09:06', 'Presentation End Time': '09:18', 'Presentation ID': 705, 'Presentation Number': 'OP045', 'Presentation Title': 'EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY AMONG GUSELKUMAB INDUCTION WEEK 24 CLINICAL RESPONDERS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY', 'Presentation Title (lowercase)': 'efficacy and safety of guselkumab maintenance therapy among guselkumab induction week 24 clinical responders: results from the phase 3 quasar maintenance study', 'Abstract Authors': 'Tadakazu Hisamatsu', 'Abstract Affiliations': 'Kyorin University School of Medicine', 'Abstract': '<i>D.T. Rubin<sup>1</sup>, A. Dignass<sup>2</sup>, J. Allegretti<sup>3</sup>, S. Yarandi<sup>4</sup>, K.-H. Huang<sup>4</sup>, M. Germinaro<sup>4</sup>, J. Zhan<sup>4</sup>, H. Zhang<sup>4</sup>, Y. Rayyan<sup>5</sup>, M. Saruta<sup>6</sup>, D. Balderramo<sup>7</sup>, B. Bressler<sup>8</sup>, L. Peyrin-Biroulet<sup>9</sup>, <u>T. Hisamatsu</u><sup>10</sup></i><br>\\r\\n<div><sup>1</sup>University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States of America, <sup>2</sup>Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany, <sup>3</sup>Brigham and Women\\'s Hospital Crohn\\'s and Colitis Center, Boston, United States of America, <sup>4</sup>Janssen Research & Development, LLC, Spring House, United States of America, <sup>5</sup>The University of Jordan, School of Medicine, Amman, Jordan, <sup>6</sup>The Jikei University School of Medicine, Tokyo, Japan, <sup>7</sup>Hospital Privado Universitario de Córdoba, Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina, <sup>8</sup>University of British Columbia, Vancouver, Canada, <sup>9</sup>Nancy University Hospital, Université de Lorraine, Nancy, France, <sup>10</sup>Kyorin University School of Medicine, Tokyo, Japan<br><br></div>\\r\\n\\r\\n            <div><strong>Introduction</strong>:&nbsp;The QUASAR program (NCT04033445) evaluated guselkumab (GUS), a dual-acting interleukin (IL)-23p19 subunit inhibitor that potently neutralizes IL-23 and binds to CD64 (a receptor on cells that produce IL-23), in patients (pts) with moderately to severely active ulcerative colitis (UC). Induction Week 12 (Week I-12) nonresponders to intravenous (IV) GUS received subcutaneous (SC) GUS through Week I-24.<sup >1</sup> Week I‑24 responders were eligible for maintenance therapy. Here, we present the efficacy and safety of maintenance SC GUS among GUS Week I-24 responders.</div>\\r\\n                <div><strong>Aims & Methods</strong>:&nbsp;Pts who were not in clinical response (see Table for definition) at Week I-12 after IV GUS 200 mg or 400 mg received SC GUS 200 mg at Weeks I-12, I-16, and I-20. Those who were in clinical response at Week I-24 (GUS Week I-24 responders) received SC GUS 200 mg every 4 weeks during the maintenance study in a blinded fashion and were evaluated as part of the nonrandomized study population. Clinical, symptomatic, endoscopic, histologic, and patient-reported outcome measures at maintenance Week 44 (Week M-44) and safety throughout the maintenance study are reported for GUS Week I-24 responders.</div>\\r\\n                <div><strong>Results</strong>:&nbsp;Overall, 123 of 203 (60.6%) Week I-12 nonresponders to IV GUS achieved clinical response at Week I-24 and entered the maintenance study phase. Induction baseline characteristics of GUS Week I-24 responders were: 74.8% had severe disease (modified Mayo score 7-9), 77.2% had a Mayo endoscopy subscore of 3, median C-reactive protein was 5.0 mg/L (upper limit of normal, 3 mg/L), and 59.3% had a history of inadequate response or intolerance to biologic or Janus kinase inhibitor therapy for UC. At Week M‑44, 67.5% of the pts maintained clinical response and 30.1% were in clinical remission. Additional efficacy outcomes are shown in the Table. The proportion of GUS Week I-24 responders in symptomatic remission (defined as a stool frequency subscore of 0 or 1 and not increased from induction baseline, and a rectal bleeding subscore of 0) at maintenance baseline (58.5%) was sustained through Week M‑44 (56.9%). Adverse events (AEs) were reported for 78.0% of GUS Week I-24 responders, serious AEs for 5.7%, and serious infections for 1.6%. No opportunistic infections or deaths occurred. No new safety concerns were identified.<br><br><table style=\"width: 100%;\" class=\"\"><thead><tr><th colspan=\"2\" style=\"width: 99.8893%;\"><strong>Table. Efficacy Outcomes at Maintenance Week 44 for GUS Induction Week 12 Nonresponders Who Achieved Clinical Response<sup>a</sup> at Induction Week 24</strong></th></tr></thead><tbody><tr><td style=\"width: 71.3178%;\"><br></td><td style=\"width: 28.5715%; text-align: center;\"><strong>GUS 200 mg SC q4w</strong><br><strong>N=123</strong><br><strong>n (%)</strong><br></td></tr><tr><td style=\"width: 71.3178%;\">Clinical remission<sup>b</sup><br></td><td style=\"width: 28.5715%; text-align: center;\" class=\"\">37 (30.1)<br></td></tr><tr><td style=\"width: 71.3178%;\">Endoscopic improvement<sup>c </sup>/ Endoscopic normalization (remission)<sup>d</sup><br></td><td style=\"width: 28.5715%; text-align: center;\">44 (35.8) / 21 (17.1)<br></td></tr><tr><td style=\"width: 71.3178%;\">Corticosteroid-free clinical remission<sup>e</sup><br></td><td style=\"width: 28.5715%; text-align: center;\">37 (30.1)<br></td></tr><tr><td style=\"width: 71.3178%;\">Maintenance of clinical response<sup>f</sup><br></td><td style=\"width: 28.5715%; text-align: center;\">83 (67.5)<br></td></tr><tr><td style=\"width: 71.3178%;\">Histologic-endoscopic muscosal improvement<sup>g</sup><br></td><td style=\"width: 28.5715%; text-align: center;\">34 (27.6)<br></td></tr><tr><td style=\"width: 71.3178%;\">Fatigue response<sup>h</sup><br></td><td style=\"width: 28.5715%; text-align: center;\">49 (39.8)<br></td></tr><tr><td style=\"width: 71.3178%;\" class=\"\">Maintenance of clinical remission<sup>i</sup>, N=20<br></td><td style=\"width: 28.5715%; text-align: center;\">10 (50.0)<br></td></tr><tr><td style=\"width: 99.8893%;\" colspan=\"2\" class=\"fr-selected-cell\">GUS=guselkumab; PROMIS=Patient-Reported Outcomes Measurement Information System; pts=patients; q4w=every 4 weeks; SC=subcutaneous; Week M-44=maintenance Week 44.<br>Note: Includes only pts with modified Mayo score 5-9 at induction baseline.<br><sup>a</sup> Clinical response was defined as a decrease from induction baseline in the modified Mayo score by ≥30% and ≥2 points, with either a ≥1-point decrease from induction baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1.<br><sup>b </sup>Clinical remission was defined as a Mayo stool frequency subscore of 0 or 1 and not increased from induction baseline, a Mayo rectal bleeding subscore of 0, and a Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.<br><sup>c </sup>Endoscopic improvement was defined as an endoscopy subscore of 0 or 1 with no friability present on the endoscopy.<br><sup>d </sup>Endoscopic normalization (remission) was defined as an endoscopy subscore of 0.<br><sup>e </sup>Corticosteroid-free clinical remission was defined as clinical remission at Week M-44 without any use of corticosteroids for ≥8 weeks prior to Week M-44.<br><sup>f </sup>Maintenance of clinical response was defined as clinical response at Week M-44 among pts in clinical response at maintenance baseline.<br><sup>g</sup> Histologic-endoscopic muscosal improvement was defined as achieving a combination of histologic improvement (defined as neutrophil infiltration in &lt;5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system [i.e., Geboes score ≤3.1]) and endoscopic improvement.<br><sup>h</sup> Fatigue response was defined as a ≥7-point improvement from induction baseline in the PROMIS Fatigue Short Form 7a.<br><sup>i </sup>Maintenance of clinical remission was defined as clinical remission at Week M-44 among pts in clinical remission at maintenance baseline.<br></td></tr></tbody></table></div>\\r\\n                <div><strong>Conclusion</strong>:&nbsp;In this refractory population of GUS Week I-24 responders, maintenance treatment with GUS provided clinical benefit across a range of clinically relevant efficacy endpoints. Safety results were consistent with the overall population and safety profile of GUS in its approved indications.</div>\\r\\n                                        <div><strong>References</strong>:&nbsp;1. Bressler B, et al. <em >Am J Gastroenterol</em>. 2023;118(10S):806-807.</div>\\r\\n                <div><strong>Nothing to disclose</strong>:&nbsp;No</div>\\r\\n                <div><strong>Disclosure</strong>:&nbsp;<strong>D. T. Rubin: </strong>research funding from Takeda; consultant to AbbVie, Altrubio, Allergan, Arena, Aslan, Athos, Bellatrix, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corp/Syneos, Connect, GalenPharma/Atlantica, Genentech/Roche, InDex, Ironwood, Iterative Scopes, Janssen, Lilly, Pfizer, Prometheus, Reistone, Takeda, and Techlab; and co-founder of Cornerstones Health.<br><strong>A. Dignass:</strong> fees for participation in clinical trials, review activities (data monitoring boards, statistical analysis, endpoint committees) from Abivax, AbbVie, Bristol Myers Squibb, Dr Falk Foundation, Galapagos, Gilead, Janssen, and Pfizer; consultancy fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Dr Falk Foundation, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Roche, Sandoz, Stada, Takeda, Tillotts, and Vifor Pharma; payment for lectures/speaker’s bureaus from AbbVie, Biogen, CED Service GmbH, Celltrion, Falk Foundation, Ferring, Galapagos, Gilead, High5MD, Janssen, Materia Prima, MedToday, MSD, Pfizer, Sandoz, Takeda, Tillotts, and Vifor Pharma; payment for manuscript preparation from Abbvie, Falk Foundation, Janssen, Takeda, Thieme, and UniMed Verlag.<br><strong>J. R. Allegretti: </strong>consultant for AbbVie, Adiso, Ferring, Finch, Iterative Scopes, Janssen, Merck, Pfizer, Roivant, and Seres Therapeutics; speaker for AbbVie, Bristol Myer Squibb, and Janssen; and research support from Janssen, Merck, and Pfizer.<br><strong>Y. Rayyan</strong>: fees for participating in clinical trials for Janssen as principal investigator and payment from lectures including service on speaker’s bureaus from Janssen, AbbVie, and Amgen.<br><strong>M. Saruta: </strong>grants or contracts from Mochida, Zeria Pharma, EA Pharma, Kissei, and EPS Corporation; and payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from AbbVie GK, Janssen, Mitsubishi Tanabe Pharma, Takeda, EA Pharma, Gilead Sciences, and Kissei.<br><strong>D. Balderramo: </strong>advisor/speaker fees from AbbVie, Janssen, Pfizer, Takeda, and Amgen; and travel/congress support from AbbVie, Janssen, Takeda, and Ferring.<br><strong>B. Bressler: </strong>advisor/speaker for AbbVie, Bristol Myers Squibb, Ferring, Janssen, Merck, Novartis, Organon, Pfizer, Sandoz, and Takeda; advisor for Alimentiv, Allergan, Amgen, AMT, Bausch Health, Bristol Myers Squibb, Celgene, Celltrion, Eupraxia Fresenius Kabi, Genentech/Roche, Gilead, Iterative Scopes, Jamp, Merck, Microbiome Insights, Mylan, Pendopharm, Protagonist, and Viatris; research support from AbbVie, Amgen, Business Intelligence, Bristol Myers Squibb, Genentech/Roche, GlaxoSmithKline, Janssen, Merck, and Qu Biologic; and holds stock options in Qu Biologic.<br><strong>L. Peyrin-Biroulet: </strong>consultant for AbbVie, Abivax, Alimentiv, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, Bristol Myers Squibb, Celltrion, Connect, Cytoki, Lilly, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech/Roche, Gilead, Gossamer Bio, GlaxoSmithKline, HAC-Pharma, IAG, InDex, Inotrem, Janssen, Medac, Mopac, Morphic, MSD, Norgine, Novartis, OM, ONO, OSE, Pandion, Par’Immune, Pfizer, Prometheus, Protagonist, Roche, Sandoz, Takeda, Theravance, Thermo Fisher, Tigenix, Tillots, Viatris, Vifor, and Ysopia; grants from Celltrion, Fresenius Kabi, and Takeda; honorarium for lectures from AbbVie, Amgen, Arena, Biogen, Celltrion, Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, Janssen, Medac, MSD, Pfizer, Sandoz, Takeda, Tillots, Viatris, and Vifor; and fees from AbbVie, Adacyte, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Celltrion, CONNECT Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, HAC-Pharma, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Norgine, Nordic Pharma, Novartis, OM Pharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Par’Immune, Pfizer, Prometheus, Protagonist, Roche, Sanofi, Sandoz, Takeda, Theravance, Thermo Fisher, Tigenix, Tillots, Viatris, Vifor, Ysopia, Abivax, Samsung, Ventyx, Roivant, and Vectivbio.<br><strong>T. Hisamatsu: </strong>grant support from AbbVie, Daiichi-Sankyo, EA Pharma, JIMRO, Mitsubishi Tanabe Pharma, Mochida, Nippon Kayaku, Pfizer, and Takeda; consulting fees from EA Pharma, Janssen Research &amp; Development, Gilead Sciences, Lilly, and Bristol Myers Squibb; and lecture fees from AbbVie, EA Pharma, Mitsubishi Tanabe Pharma, Takeda, Mochida, and Kissei.<br><strong>S. Yarandi, K.-H. G. Huang, M. Germinaro, J. Zhan, </strong>and<strong> H. Zhang: </strong>employees of Johnson &amp; Johnson and own company stock/stock options.</div>\\r\\n        <div>\\r\\n                    <br><strong>Keyword 1</strong>:&nbsp;ulcerative colitis&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 2</strong>:&nbsp;guselkumab&nbsp;&nbsp;&nbsp;\\r\\n                            <strong>Keyword 3</strong>:&nbsp;clinical response\\r\\n            </div>\\r\\n  ', 'Abstract Url': 'https://programme.ueg.eu/week2024/#/details/presentations/1690', 'Company': None, 'Asset': 'Guselkumab', 'Indication': 'IBD', 'MoA': None, 'Other Keywords': None}]\n"]}],"source":["\n","# Define the fields you want to extract for sessions and presentations combined\n","fields = [\n","    \"Session Date\", \"Session Start Time\", \"Session End Time\", \"Session Timezone\",\n","    \"Session Location\", \"Session Number\", \"Session Pathways\", \"Session Format\",\n","    \"Session CME\", \"Session Type\", \"Session Group\", \"Session Title\", \"Session Description\",\n","    \"Presentation Date\", \"Presentation Location\", \"Presentation Start Time\", \"Presentation End Time\",\n","    \"Presentation ID\", \"Presentation Number\", \"Presentation Title\", \"Abstract Authors\", \"Abstract Affiliations\", \"Presentation Title (lowercase)\",\n","    \"Abstract\", \"Abstract Url\", \"Company\", \"Asset\", \"Indication\", \"MoA\", \"Other Keywords\"\n","]\n","\n","# Initialize the combined data list\n","combined_data = []\n","\n","\n","\n","# Iterate over each session item\n","for item in dataSession:\n","    # Common session-related data (outside presentation loop)\n","    session_common_data = {\n","        \"Session Date\": item.get('day', {}).get(\"date\"),\n","        \"Session Start Time\": item.get(\"start_time\"),\n","        \"Session End Time\": item.get(\"end_time\"),\n","        \"Session Timezone\": \"CEST\",\n","        \"Session Location\": item.get(\"room\", {}).get('short_name'),\n","        \"Session Number\": item.get(\"id\"),\n","        \"Session Pathways\": ', '.join([pathway.get('name') for pathway in item.get('pathways', [])]),\n","        \"Session CME\": \"\",\n","        \"Session Type\": item.get('session_type', {}).get('name'),\n","        \"Session Group\": item.get(\"session_group_id\"),\n","        \"Session Title\": item.get(\"title\"),\n","        \"Session Description\": item.get(\"content\", {}).get(\"outline\"),\n","    }\n","\n","    for presentation in item.get('presentations', []):\n","        \n","        abstracts = {}\n","        Abstract_url = None\n","        Abstract_id = presentation.get(\"presentation\", {}).get(\"abstract_id\")\n","        if (Abstract_id):\n","            Abstract_url = f\"https://programme.ueg.eu/week2024/#/details/presentations/{Abstract_id}\"\n","            Abstract_endpoint = f\"https://ueg2024.abstract.documedias.systems/api/v1/manager/abstract/multi/html/id/{Abstract_id}/template/planner_preview?program_type=week&system=program_week_2024\"\n","            responseAbstract = requests.get(Abstract_endpoint)\n","            dataAbstract = responseAbstract.json()\n","\n","            abstracts = dataAbstract.get(f\"{Abstract_id}\")\n","            print(abstracts)\n","\n","        authors = []\n","        institutions = []\n","\n","        for person in presentation.get('presentation', {}).get('persons', []):\n","            #print(person)\n","            institution = person.get('person', {}).get('institution')\n","            author_name = person.get('person', {}).get('first_name') + ' ' + person.get('person', {}).get('last_name')\n","            if institution:\n","                institutions.append(institution)\n","                #print(institutions)\n","            if author_name:\n","                authors.append(author_name)\n","\n","            presentation_title = presentation.get(\"presentation\", {}).get(\"title\", \"\")\n","            session_title = item.get(\"title\", \"\")\n","            session_description = item.get(\"content\", {}).get(\"outline\", \"\")\n","\n","            matched_indication = find_matching_keyword(presentation_title, indication) or \\\n","                                find_matching_keyword(session_title, indication) or \\\n","                                find_matching_keyword(session_description, indication)\n","\n","            matched_asset = find_matching_keyword(presentation_title, asset) or \\\n","                            find_matching_keyword(session_title, asset) or \\\n","                            find_matching_keyword(session_description, asset)\n","\n","            matched_company = find_matching_keyword(presentation_title, company_name) or \\\n","                            find_matching_keyword(session_title, company_name) or \\\n","                            find_matching_keyword(session_description, company_name)\n","\n","            matched_MoA = find_matching_keyword(presentation_title, MoA) or \\\n","                        find_matching_keyword(session_title, MoA) or \\\n","                        find_matching_keyword(session_description, MoA)\n","\n","            matched_other_keywords = find_matching_keyword(presentation_title, other_keywords) or \\\n","                                    find_matching_keyword(session_title, other_keywords) or \\\n","                                    find_matching_keyword(session_description, other_keywords)\n","\n","\n","        presentation_data = {\n","            **session_common_data,  # Include session data in each presentation entry\n","            \"Session Format\": ', '.join([format.get('name') for format in item.get('formats', [])]),\n","            \"Presentation Date\": item.get('day', {}).get(\"date\"),\n","            \"Presentation Location\": item.get(\"room\", {}).get('short_name'),\n","            \"Presentation Start Time\": presentation.get(\"start_time\"),\n","            \"Presentation End Time\": presentation.get(\"end_time\"),\n","            \"Presentation ID\": presentation.get(\"id\"),\n","            \"Presentation Number\": presentation.get(\"code\"),\n","            \"Presentation Title\": presentation.get(\"presentation\", {}).get(\"title\"),\n","            \"Presentation Title (lowercase)\": presentation.get(\"presentation\", {}).get(\"title\", '').lower(),\n","            \"Abstract Authors\":', '.join(authors),\n","            \"Abstract Affiliations\": ', '.join(institutions),  # Join institutions into a string\n","            \"Abstract\": abstracts,  # IF ABSTRACT_ID:\n","            \"Abstract Url\": Abstract_url,\n","            \"Company\": matched_company,\n","            \"Asset\": matched_asset,\n","            \"Indication\": matched_indication,\n","            \"MoA\": matched_MoA,\n","            \"Other Keywords\": matched_other_keywords,\n","        }\n","\n","\n","\n","        #print(author_name)\n","        print(combined_data)\n","        # Append combined data\n","        combined_data.append(presentation_data)"]},{"cell_type":"code","execution_count":24,"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"collapsed":true,"executionInfo":{"elapsed":308,"status":"ok","timestamp":1728940741006,"user":{"displayName":"Cyro Queiroz","userId":"10205326658499773298"},"user_tz":180},"id":"WsWafeKiX_rT","outputId":"89b1e526-3331-4ebe-c307-66f775a21f8e"},"outputs":[{"name":"stdout","output_type":"stream","text":["  Session Date Session Start Time Session End Time Session Timezone  \\\n","0   2024-10-14              08:30            09:30             CEST   \n","1   2024-10-14              08:30            09:30             CEST   \n","2   2024-10-14              08:30            09:30             CEST   \n","3   2024-10-14              08:30            09:30             CEST   \n","4   2024-10-14              08:30            09:30             CEST   \n","\n","  Session Location  Session Number Session Pathways        Session Format  \\\n","0               A3              80              IBD  Live, Recording, Q&A   \n","1               A3              80              IBD  Live, Recording, Q&A   \n","2               A3              80              IBD  Live, Recording, Q&A   \n","3               A3              80              IBD  Live, Recording, Q&A   \n","4               A3              80              IBD  Live, Recording, Q&A   \n","\n","  Session CME      Session Type  ...           Abstract Authors  \\\n","0      Pfizer  Abstract Session  ...             Bruce E. Sands   \n","1      Pfizer  Abstract Session  ...  Manuel Barreiro de Acosta   \n","2      Pfizer  Abstract Session  ...             David T. Rubin   \n","3      Pfizer  Abstract Session  ...         Tadakazu Hisamatsu   \n","4      Pfizer  Abstract Session  ...              David Laharie   \n","\n","                               Abstract Affiliations  \\\n","0            Icahn School of Medicine at Mount Sinai   \n","1  Health Research Institute of Santiago de Compo...   \n","2                     University of Chicago Medicine   \n","3               Kyorin University School of Medicine   \n","4  CHU de Bordeaux Hopital Haut-Leveque Dept. de ...   \n","\n","                      Presentation Title (lowercase)  \\\n","0  efficacy of guselkumab versus placebo in crohn...   \n","1  real-world short-term effectiveness of risanki...   \n","2  extended induction response over time in patie...   \n","3  efficacy and safety of guselkumab maintenance ...   \n","4  corticosteroid-sparing effect of mirikizumab f...   \n","\n","                                            Abstract  \\\n","0  <i><u>B.E. Sands</u><sup>1</sup>, G. D’Haens<s...   \n","1  <i><u>M. Barreiro-de Acosta</u><sup>1,2</sup>,...   \n","2  <i><u>D.T. Rubin</u><sup>1</sup>, A. Charabaty...   \n","3  <i>D.T. Rubin<sup>1</sup>, A. Dignass<sup>2</s...   \n","4  <i><u>D. Laharie</u><sup>1</sup>, C.A Siegel<s...   \n","\n","                                        Abstract Url Company         Asset  \\\n","0  https://programme.ueg.eu/week2024/#/details/pr...    None    Guselkumab   \n","1  https://programme.ueg.eu/week2024/#/details/pr...    None  Risankizumab   \n","2  https://programme.ueg.eu/week2024/#/details/pr...    None   Mirikizumab   \n","3  https://programme.ueg.eu/week2024/#/details/pr...    None    Guselkumab   \n","4  https://programme.ueg.eu/week2024/#/details/pr...    None   Mirikizumab   \n","\n","           Indication   MoA Other Keywords  \n","0               Crohn  None           None  \n","1               Crohn  None           None  \n","2  Ulcerative Colitis  None           None  \n","3                 IBD  None           None  \n","4  Ulcerative Colitis  None           None  \n","\n","[5 rows x 30 columns]\n"]}],"source":["# Create a DataFrame from the combined data list\n","df_combined = pd.DataFrame(combined_data, columns=fields)\n","\n","# Export the DataFrame to an Excel file\n","df_combined.to_excel(\"UEG_Scrape_Combined.xlsx\", sheet_name=\"Combined Data\", index=False)\n","\n","# Display the DataFrame (for debugging purposes)\n","print(df_combined)"]}],"metadata":{"colab":{"authorship_tag":"ABX9TyM8UexKAcrIDLVHZuir5IVg","provenance":[]},"kernelspec":{"display_name":".venv","language":"python","name":"python3"},"language_info":{"codemirror_mode":{"name":"ipython","version":3},"file_extension":".py","mimetype":"text/x-python","name":"python","nbconvert_exporter":"python","pygments_lexer":"ipython3","version":"3.12.3"}},"nbformat":4,"nbformat_minor":0}
